

**PHP\_2.01.98 Orthopedic Applications of Platelet-Rich Plasma**

Original Policy Date:	December 1, 2025	Effective Date:	December 1, 2025
Section:	2.0 Medicine	Page:	Page 1 of 44

**State Guidelines**

As of the publication of this policy, there are no applicable Medi-Cal guidelines (Provider Manual or All Plan Letter). Please refer to the Policy Statement section below.

**Policy Statement**

**In the absence of any State Guidelines, please refer to the criteria below.**

- I. Use of platelet-rich plasma is considered **investigational** for all orthopedic indications. This includes, but is not limited to, use in the following situations:
  - A. Primary use (injection) for the following conditions:
    1. Achilles tendinopathy
    2. Lateral epicondylitis
    3. Plantar fasciitis
    4. Osteochondral lesions
    5. Osteoarthritis
  - B. Adjunctive use in the following surgical procedures:
    1. Anterior cruciate ligament (ACL) reconstruction
    2. Hip fracture
    3. Long-bone nonunion
    4. Patellar tendon repair
    5. Rotator cuff repair
    6. Spinal fusion
    7. Subacromial decompression surgery
    8. Total knee arthroplasty (TKA)

**Policy Guidelines****Coding**

See the [Codes table](#) for details.

**Description**

The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

**Summary of Evidence****Primary Treatment for Tendinopathies**

For individuals with tendinopathy who receive platelet-rich plasma injections, the evidence includes multiple randomized controlled trials (RCTs) and systematic reviews with meta-analyses. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-

related morbidity. Findings from meta-analyses of RCTs have been mixed and have generally found that platelet-rich plasma did not have a statistically and/or clinically significant impact on symptoms (i.e., pain) or functional outcomes. Findings from a subsequently published RCT failed to find improvement compared with placebo. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Primary Treatment for Non-Tendon Soft Tissue Injury or Inflammation**

For individuals with non-tendon soft tissue injury or inflammation (e.g., plantar fasciitis) who receive platelet-rich plasma injections, the evidence includes several small RCTs, multiple prospective observational studies, and systematic reviews. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The 2014 systematic review, which identified 3 RCTs on platelet-rich plasma for plantar fasciitis, did not pool study findings. Results among the remaining RCTs were inconsistent. The largest RCT showed that treatment using platelet-rich plasma compared with corticosteroid injection resulted in statistically significant improvement in pain and disability, but not quality of life. A 2023 systematic review found improved visual analog scale (VAS) scores with platelet-rich plasma compared to corticosteroid injections out to 6 months duration, but numerical differences between groups were small. Larger RCTs completed over a sufficient duration of time (i.e., 2 years) are still needed to address important uncertainties in efficacy and safety. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Primary Treatment for Osteochondral Lesions**

For individuals with osteochondral lesions who receive platelet-rich plasma injections, the evidence includes an open-labeled quasi-randomized study. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The quasi-randomized study found a statistically significant greater impact on outcomes in the platelet-rich plasma group than in the hyaluronic acid group. Limitations of the evidence base include lack of adequately randomized studies, lack of blinding, lack of sham controls, and comparison only to an intervention of uncertain efficacy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Primary Treatment for Knee or Hip Osteoarthritis**

For individuals with knee or hip osteoarthritis who receive platelet-rich plasma injections, the evidence includes multiple RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. Most trials have compared platelet-rich plasma with hyaluronic acid for knee osteoarthritis. Systematic reviews have generally found that platelet-rich plasma was more effective than placebo or hyaluronic acid in reducing pain and improving function. However, systematic review authors have noted that their findings should be interpreted with caution due to important limitations including significant residual statistical heterogeneity, questionable clinical significance, and high risk of bias in study conduct. RCTs with a follow-up of at least 12 months published subsequent to the systematic reviews found statistically significantly greater 12-month reductions in pain and function outcomes, but these findings were also limited by important study conduct flaws including potential inadequate control for selection bias and limited or unclear blinding. Also, benefits were not maintained at 5 years. Using hyaluronic acid as a comparator is questionable because the evidence demonstrating the benefit of hyaluronic acid treatment for osteoarthritis is not robust. Two systematic reviews evaluating hip osteoarthritis did not report any statistically or clinically significant differences in pain or functional outcomes compared to hyaluronic acid, corticosteroids, or placebo. Additional studies comparing platelet-rich plasma with placebo and with alternatives other than hyaluronic acid are needed to determine the efficacy of platelet-rich plasma for knee and hip osteoarthritis. Studies are also needed to determine the optimal protocol for delivering platelet-rich plasma. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Adjunct to Surgery

For individuals with anterior cruciate ligament reconstruction who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes several systematic reviews of multiple RCTs and prospective studies and a retrospective matched case-control study. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. In 2 systematic reviews that conducted a meta-analysis, adjunctive platelet-rich plasma treatment did not result in a significant effect on International Knee Documentation Committee (IKDC) scores, a patient-reported, knee-specific outcome measure that assesses pain and functional activity. One systematic review found improvements with platelet-rich plasma compared to controls in outcomes at 6 months, but these differences were determined to be clinically irrelevant with the exception of pain at 6 months which was improved with platelet-rich plasma. Individual trials have shown mixed results. A retrospective matched case-control study found no differences in knee function scores or time to return of activity between platelet-rich plasma and matched-control groups at 2 years; however, the platelet-rich plasma group demonstrated a higher rate of postoperative knee motion loss compared with the control group. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with hip fracture who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes an open-labeled RCT. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The single open-label RCT failed to show a statistically significant reduction in the need for surgical revision with the addition of platelet-rich plasma treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with long bone nonunion who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes 3 RCTs. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. One trial with a substantial risk of bias failed to show significant differences in patient-reported or clinician-assessed functional outcome scores between patients who received platelet-rich plasma plus allogenic bone graft versus those who received only allogenic bone graft. While the trial showed statistically significant increases in the proportion of bones that healed in patients receiving platelet-rich plasma in a modified intention-to-treat analysis, the results did not differ in the intention-to-treat analysis. An RCT that compared platelet-rich plasma with recombinant human bone morphogenetic protein-7 (rhBMP-7) also failed to show any clinical and radiologic benefits of platelet-rich plasma over rhBMP-7. The third RCT found no difference in the number of unions or time to union in patients receiving platelet-rich plasma injections or no treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with rotator cuff repair who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes multiple RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. Although systematic reviews consistently found significant reductions in pain with platelet-rich plasma at 12 months, important study conduct and relevance weaknesses limit interpretation of these findings. While the systematic reviews and meta-analyses generally failed to show a statistically and/or clinically significant impact on other outcomes, 1 meta-analysis found a statistically significant reduction in retear rate in a subgroup analysis of 4 RCTs that were at least 24 months in duration. The findings of a subsequently published 10-year follow-up of a small RCT failed to demonstrate the superiority of platelet-rich plasma over control for clinical and radiologic outcomes. Two newer RCTs also found no difference in the addition of platelet-rich plasma over control in functional outcomes at either 6 months or 1 year follow-up. The variability in platelet-rich plasma preparation techniques and platelet-rich plasma administration limits the generalizability of the available evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals undergoing spinal fusion who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes a single small RCT and a few observational studies. Relevant outcomes include symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. Studies have generally failed to show a statistically and/or clinically significant impact on symptoms (i.e., pain). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with subacromial decompression surgery who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes a small RCT. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. A single small RCT failed to show a reduction in self-assessed or physician-assessed spinal instability scores with platelet-rich plasma injections. However, subjective pain, use of pain medications, and objective measures of range of motion showed clinically significant improvements with platelet-rich plasma. Larger trials are required to confirm these benefits. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with total knee arthroplasty who receive platelet-rich plasma injections plus orthopedic surgery, the evidence includes systematic reviews. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The reviews showed no significant differences between the platelet-rich plasma and untreated control groups in range of motion, functional outcomes, and long-term pain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **Additional Information**

Not applicable.

#### **Related Policies**

- Bone Morphogenetic Protein

#### **Benefit Application**

Blue Shield of California Promise Health Plan is contracted with L.A. Care Health Plan for Los Angeles County and the Department of Health Care Services for San Diego County to provide Medi-Cal health benefits to its Medi-Cal recipients. In order to provide the best health care services and practices, Blue Shield of California Promise Health Plan has an extensive network of Medi-Cal primary care providers and specialists. Recognizing the rich diversity of its membership, our providers are given training and educational materials to assist in understanding the health needs of their patients as it could be affected by a member's cultural heritage.

The benefit designs associated with the Blue Shield of California Promise Medi-Cal plans are described in the Member Handbook (also called Evidence of Coverage).

#### **Regulatory Status**

The U.S. Food and Drug Administration (FDA) regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1,270 and 1,271. Blood products such as platelet-rich plasma are included in these regulations. Under these regulations, certain products including blood

products such as platelet-rich plasma are exempt and therefore do not follow the traditional FDA regulatory pathway. To date, the FDA has not attempted to regulate activated platelet-rich plasma.

A number of platelet-rich plasma preparation systems are available, many of which were cleared for marketing by the FDA through the 510(k) process for producing platelet-rich preparations intended to be mixed with bone graft materials to enhance the bone grafting properties in orthopedic practices. The use of platelet-rich plasma outside of this setting (e.g., an office injection) would be considered off-label. The Aurix System® (previously called AutoloGel™; Nuo Therapeutics) and SafeBlood® (SafeBlood Technologies) are 2 related but distinct autologous blood-derived preparations that can be used at the bedside for immediate application. Both AutoloGel™ and SafeBlood® have been specifically marketed for wound healing. Other devices may be used during surgery (e.g., autoLog® Autotransfusion system [Medtronic], the SmartPRePÒ [Harvest Technologies] device). The Magellan® Autologous Platelet Separator System (Isto Biologics) includes a disposable kit for use with the Magellan Autologous Platelet Separator portable tabletop centrifuge. GPS® II (BioMet Biologics), a gravitational platelet separation system, was cleared for marketing by the FDA through the 510(k) process for use as disposable separation tube for centrifugation and a dual cannula tip to mix the platelets and thrombin at the surgical site (GPS® III [Zimmer Biomet] is now available). Filtration or plasmapheresis may also be used to produce platelet-rich concentrates. The use of different devices and procedures can lead to variable concentrations of activated platelets and associated proteins, increasing variability between studies of clinical efficacy.

## Health Equity Statement

Blue Shield of California Promise Health Plan's mission is to transform its health care delivery system into one that is worthy of families and friends. Blue Shield of California Promise Health Plan seeks to advance health equity in support of achieving Blue Shield of California Promise Health Plan's mission.

Blue Shield of California Promise Health Plan ensures all Covered Services are available and accessible to all members regardless of sex, race, color, religion, ancestry, national origin, ethnic group identification, age, mental disability, physical disability, medical condition, genetic information, marital status, gender, gender identity, or sexual orientation, or identification with any other persons or groups defined in Penal Code section 422.56, and that all Covered Services are provided in a culturally and linguistically appropriate manner.

## Rationale

### Background

#### Platelet-Rich Plasma

A variety of growth factors have been found to play a role in wound healing, including platelet-derived growth factors, epidermal growth factor, fibroblast growth factors, transforming growth factors, and insulin-like growth factors. Autologous platelets are a rich source of platelet-derived growth factor, transforming growth factors that function as a mitogen for fibroblasts, smooth muscle cells, osteoblasts, and vascular endothelial growth factors. Recombinant platelet-derived growth factor has also been extensively investigated for clinical use in wound healing.

Autologous platelet concentrate suspended in plasma, also known as platelet-rich plasma, can be prepared from samples of centrifuged autologous blood. Exposure to a solution of thrombin and calcium chloride degranulates platelets, releasing the various growth factors. The polymerization of fibrin from fibrinogen creates a platelet gel, which can then be used as an adjunct to surgery with the intent of promoting hemostasis and accelerating healing. In the operating room setting, platelet-rich plasma has been investigated as an adjunct to various periodontal, reconstructive, and orthopedic procedures. For example, bone morphogenetic proteins are a type of transforming growth factor, and thus platelet-rich plasma has been used in conjunction with bone-replacement grafting (using

either autologous grafts or bovine-derived xenograft) in periodontal and maxillofacial surgeries. Alternatively, platelet-rich plasma may be injected directly into various tissues. Platelet-rich plasma injections have been proposed as a primary treatment of miscellaneous conditions, such as epicondylitis, plantar fasciitis, and Dupuytren contracture.

Injection of platelet-rich plasma for tendon and ligament pain is theoretically related to prolotherapy. However, prolotherapy differs in that it involves the injection of chemical irritants intended to stimulate inflammatory responses and induce the release of endogenous growth factors.

Platelet-rich plasma is distinguished from fibrin glues or sealants, which have been used as a surgical adjunct to promote local hemostasis at incision sites. Fibrin glue is created from platelet-poor plasma and consists primarily of fibrinogen. Commercial fibrin glues are created from pooled homologous human donors; Tisseel® (Baxter) and VITASEAL™ (Johnson & Johnson Surgical Technologies) are examples of commercially available fibrin sealants. Autologous fibrin sealants can be created from platelet-poor plasma. This evidence review does not address the use of fibrin sealants.

### **Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

At present, there are a large number of techniques available for the preparation of platelet-rich plasma or platelet-rich plasma gel. The amount and mixture of growth factors produced by different cell-separating systems vary, and it is also uncertain whether platelet activation before the injection is necessary.<sup>1,2,3,4,5,6</sup>

### **Platelet-Rich Plasma as a Primary Treatment for Tendinopathy Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, and anti-inflammatory agents, in individuals with tendinopathy.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with tendinopathy.

### ***Interventions***

The therapy being considered is platelet-rich plasma injections. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### ***Comparators***

Comparators of interest include nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, and anti-inflammatory agents.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections as a treatment for tendinopathy has varying lengths of follow-up, ranging from 6 months to 2 years. While studies described below all reported at least 1 outcome of interest, longer follow-up is necessary to fully observe outcomes.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Systematic Reviews**

Many systematic reviews have evaluated platelet-rich plasma for treating mixed tendinopathies. They include trials on tendinopathies of the Achilles, rotator cuff, patella, and/or lateral epicondyle (tennis elbow). Select, recent (i.e., 2019 to present) systematic reviews of RCTs and/or nonrandomized studies are described next. A crosswalk of RCTs included in these systematic reviews is found in the Appendix (Table A1). Characteristics and results of these systematic reviews are found in Tables 1 and 2.

Masiello et al (2022) conducted a systematic review and meta-analysis of 33 RCTs (N=2025) comparing ultrasound-guided platelet-rich plasma to control (injection of steroids, saline, autologous whole blood, mesenchymal stem cells, or local anesthetic; dry needling; prolotherapy; or other non-injection intervention) for the treatment of tendinopathy.<sup>7</sup> Tendinopathies included lateral epicondylitis (n=8), plantar fasciitis (n=5), Achilles tendinopathy (n=5), rotator cuff tendinopathy (n=7), patellar tendinopathy (n=3), and carpal tunnel syndrome (n=3). Most trials (n=20) administered platelet-rich plasma as a single injection; however, up to 4 injections were administered in some trials. Few differences in efficacy between control and platelet-rich plasma were found with the exception of patients with carpal tunnel where pain and severity scores were reduced in the short and medium term. Results were reported for individual tendinopathies and, therefore, are not included in Table 2. However, overall mean differences in pain scores were: -0.24 (95% confidence interval [CI], -0.73 to 0.25) for lateral epicondylitis, -3.62 (95% CI, -8.16 to 0.91) for plantar fasciitis, -0.17 (95% CI, -4.25 to 3.90) for Achilles tendinopathy, 0.16 (95% CI, -0.18 to 0.50) for rotator cuff tendinopathy, 0.17 (95% CI, -0.64 to 0.98) for patellar tendinopathy, and -0.24 (95% CI, -0.32 to -0.16) for carpal tunnel syndrome. The evidence was rated as low quality due to risk of bias, imprecision, and inconsistency.

Dai et al (2023) conducted a systematic review and meta-analysis of RCTs evaluating platelet-rich plasma versus control (saline injection, dry needling, or no treatment) for the treatment of tendinopathy.<sup>8</sup> A total of 13 trials met the eligibility criteria and included patients with lateral epicondylitis (5 RCTs), Achilles tendinopathy (4 RCTs), rotator cuff tendinopathy (2 RCTs), and patellar tendinopathy (2 RCTs). Among the 13 RCTs, 7 studies were judged to be at low risk of bias and 6 were found to have a high risk of bias. The meta-analysis demonstrated that platelet-rich plasma was not superior to control for the primary outcomes of change in pain intensity or function at 12 weeks; these trends also persisted at 24 weeks. The authors noted that included trials displayed significant heterogeneity with respect to platelet-rich plasma preparation and patient characteristics, and had important methodological limitations.

Muthu et al (2021) conducted a systematic review with meta-analysis of RCTs comparing platelet-rich plasma, autologous blood, corticosteroids, local anesthetics, laser therapy, and surgery for patients with lateral epicondylitis.<sup>9</sup> A total of 25 trials met the eligibility criteria (N=2040). Results demonstrated that based on data from 22 trials, only leukocyte-rich platelet-rich plasma significantly improved visual analog scale (VAS) pain scores compared to saline control (weighted mean difference [MD], -14.8; 95% CI, -23.18 to -6.39); in a subgroup analysis of 14 studies with at least 12 months of follow up, the weighted MD did not reach statistical significance (-7.69; 95% CI, -27.28 to 11.90). Based on data from 11 trials, none of the interventions were superior to saline control for improvement in the Disabilities of the Arm, Shoulder and Hand (DASH) score. Treatment ranking based on the P-score approach demonstrated that leukocyte-rich platelet-rich plasma was most likely to be the best treatment amongst autologous blood, corticosteroids, laser therapy, local anesthetics, and leukocyte-poor platelet-rich plasma.

Johal et al (2019) conducted a systematic review and meta-analysis of RCTs on platelet-rich plasma for various orthopedic indications, including 10 RCTs of lateral epicondylitis.<sup>10</sup> The meta-analysis evaluated the standardized MD in pain at both 3 and 12 months. Systematic review authors used the Cochrane Collaboration risk of bias tool to assess study quality. At 12 months, pain scores were statistically significantly lower for platelet-rich plasma versus its comparators (i.e., steroids, whole blood, dry needling, local anesthetics). However, these results should be interpreted with caution due to important limitations including high statistical heterogeneity ( $\rho =73\%$ ), lack of a clinically significant difference (i.e., < effect size threshold of 0.5 for a clinically important difference), and moderate to high risk of bias in study conduct.

**Table 1. Systematic Reviews & Meta-Analysis Characteristics**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Masiello et al (2022) <sup>7</sup>	Through 2021	33	Patients with tendinopathy	2025 (NR)	RCT	3 to 36 mo
Dai et al (2023) <sup>8</sup>	2010-2020	13	Patients with tendinopathy	576 (23 to 79)	RCT	4 to $\geq 24$ wk
Muthu et al (2021) <sup>9</sup>	2010-2020	25	Patients with lateral epicondylitis	2040 (25 to 230)	RCT	3 to 24 mo
Johal et al (2019) <sup>10</sup>	2010-2016	10	Patients with lateral epicondylitis	25 to 231	RCT	6 wk to 24 mo

NR: not reported; RCT: randomized controlled trial.

**Table 2. Systematic Reviews & Meta-Analysis Results**

Study	SMD in Pain for PRP	SMD in functional disability for PRP	WMD in pain reduction (between LR-PRP and control)	WMD in functional disability (between LR-PRP and control)	WMD in pain reduction at 3 months (between LR-PRP and control)	WMD in pain reduction at 1 year (between LR-PRP and control)
Dai et al (2023) <sup>8</sup>	-0.14	0.18				
95% CI	-0.55 to 0.26	-0.13 to 0.49				

Muthu et al (2021) <sup>9</sup>	-14.8	-8.77	-7.69
95% CI	-23.18 to -6.39	-30.60 to 13.07	-27.28 to 11.90
Johal et al (2019) <sup>10</sup>	-0.69		
95% CI	-1.15 to -0.23		

CI: confidence interval; LR: leukocyte-rich; PRP: platelet-rich plasma; SMD: standard mean difference; WMD: weighted mean difference;

### Randomized Controlled Trials

One larger RCT not included in the above systematic reviews was published in 2021 (N=240) comparing platelet-rich plasma to sham control.<sup>11</sup> Victorian Institute of Sport Assessment-Achilles (VISA-A) score was not significantly different between groups. Tables 3 and 4 summarize the RCT characteristics and results, respectively, and Tables 5 and 6 describe study design and conduct limitations.

**Table 3. Summary of Key RCT Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions	Comparator
Kearney et al (2021) <sup>11</sup>	UK	24	2016–2020	Adults with painful midportion Achilles tendinopathy lasting longer than 3 months	Active PRP (n=121)	Comparator 1 Sham (n=119)

PRP: platelet-rich plasma; RCT: randomized controlled trial; UK: United Kingdom.

**Table 4. Summary of Key RCT Results**

Study	Other pain / disability assessment
Kearney et al (2021) <sup>11</sup>	6 mo VISA-A score
PRP	54.4
Sham	53.4
Adjusted MD; 95% CI	-2.7 (-8.8 to 3.3)

CI: confidence interval; MD: mean difference; PRP: platelet-rich plasma; RCT: randomized controlled trial; VISA-A: Victorian Institute of Sport Assessment-Achilles score..

**Table 5. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow Up <sup>e</sup>
Kearney et al (2021) <sup>11</sup>	1. 37 participants received additional treatments during the 6-month follow up	1. 40 participants received additional treatments during the 6-month follow up			

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 6. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow Up <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Kearney et al (2021) <sup>11</sup>		1. Single blinded (participants only)				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference. 4. Underpowered

<sup>f</sup> Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated

### **Section Summary: Platelet-Rich Plasma as a Primary Treatment of Tendinopathy**

Multiple RCTs and systematic reviews with meta-analyses have evaluated the efficacy of platelet-rich plasma injections in individuals who have tendinopathy. The majority of the more recently published systematic reviews and meta-analyses that only included RCTs failed to show a statistically and/or clinically significant impact on symptoms (i.e., pain) or functional outcomes. Although 1 systematic review found statistically significantly lower pain scores at 12 months with platelet-rich plasma versus the comparators, its results should be interpreted with caution due to important study conduct limitations. Additionally, in a recent RCT compared to sham control, platelet-rich plasma did not significantly improve pain after 6 or 12 months.

### **Platelet-Rich Plasma as a Primary Treatment of Non-Tendon Soft Tissue Injury or Inflammation Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, and anti-inflammatory agents, in individuals with non-tendon soft tissue injury or inflammation (e.g., plantar fasciitis).

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with non-tendon soft tissue injury or inflammation (e.g., plantar fasciitis).

#### ***Interventions***

The therapy being considered is platelet-rich plasma injections. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

#### ***Comparators***

Comparators of interest include nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, and anti-inflammatory agents.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections as a treatment for non-tendon soft tissue injury or inflammation (e.g., plantar fasciitis) has varying lengths of follow-up. While studies described below all reported at least 1

outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 2 years of follow-up is considered necessary to demonstrate efficacy.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

In individuals with non-tendon soft tissue injury or inflammation (e.g., plantar fasciitis), there are no large double-blind RCTs of sufficient duration (i.e., 2 years) to demonstrate efficacy.

### Systematic Reviews

Seth et al (2023) published a systematic review comparing corticosteroid injections to either platelet-rich plasma or extracorporeal shock wave therapy in patients with plantar fasciitis.<sup>12</sup> The studies were limited to RCTs up to April 2021. A total of 18 studies were included, 12 of which evaluated platelet-rich plasma compared to corticosteroid injections. VAS scores were higher in the corticosteroid group than the platelet-rich plasma group at both 3 (MD, 0.62; 95% CI, 0.13 to 1.12;  $p=.01$ ) and 6 months (MD, 1.49; 95% CI, 0.22 to 2.76;  $p=.02$ ). Notably, numerical differences between groups were small.

Functional outcomes were similar with corticosteroids compared to platelet-rich plasma at 3 months but worse with corticosteroids at 6 months (American Orthopaedic Foot and Ankle Society [AOFAS] MD, -11.53; 95% CI, -16.62 to -6.43;  $p<.0001$ ). The authors deemed the evidence very low quality, and most studies had either high or unclear risk of bias.

### Randomized Controlled Trials

There are several additional RCTs not included in the Seth et al (2023) review.<sup>13,14,15</sup> None were large double-blind RCTs of sufficient duration (i.e., 2 years) to conclusively demonstrate efficacy. The RCTs compared platelet-rich plasma treatment with corticosteroid injection or saline injection. The platelet-rich plasma protocols differed across RCTs. The RCTs were small, ranging in size from 28<sup>15</sup> to 155 participants.<sup>13</sup> Follow-up duration ranged from 6 months<sup>15,16</sup> to 18 months.<sup>14</sup> Two were conducted in single centers in either the United Kingdom<sup>15</sup> or India.<sup>14</sup> The other was a multicenter RCT of 5 sites in the Netherlands.<sup>15</sup> None prespecified any methods to assess potential harms. Results were mixed across RCTs. The largest RCT (N=115) by Peerbooms et al (2019) compared platelet-rich plasma with corticosteroid injection and had a follow-up to 12 months.<sup>13</sup> In the RCT by Peerbooms et al (2019), the proportion of patients with at least a 25% improvement in Foot Function Index Pain Scores between baseline and 12 months was significantly greater in the platelet-rich plasma group (88.4% vs. 55.6%;  $p=.003$ ). Additionally, mean Foot Function Index Disability Scores were significantly lower in the platelet-rich plasma group at 12 months (MD, 12.0; 95% CI, 2.3 to 21.6). But these improvements did not translate into significantly greater quality of life in the platelet-rich plasma group. Also, important study design and conduct gaps exist that seriously limit the interpretation of these findings, including that analysis excluded 29% of the randomized patients, which was less than the calculated sample size. Therefore, although evidence continues to develop, important uncertainties in efficacy and safety remain and larger double-blind RCTs are still needed.

### Section Summary: Platelet-Rich Plasma as a Primary Treatment of Non-Tendon Soft Tissue Injury or Inflammation

Several small RCTs, multiple prospective observational studies, and systematic reviews of these studies have evaluated the efficacy of platelet-rich plasma injections in individuals with chronic plantar fasciitis. The preparation of platelet-rich plasma and outcome measures differed across

studies. Results among the RCTs were inconsistent. The largest of the RCTs showed that treatment using platelet-rich plasma compared with corticosteroids resulted in statistically significant improvements in pain and disability, but not quality of life. Larger RCTs completed over a sufficient duration of time (i.e., 2 years) are still needed to address important uncertainties in efficacy and safety.

## Platelet-Rich Plasma as a Primary Treatment of Osteochondral Lesions

### Clinical Context and Therapy Purpose

The purpose of platelet-rich plasma injections is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, anti-inflammatory agents, and surgery in individuals with osteochondral lesions.

The following PICO was used to select literature to inform this review.

### *Populations*

The relevant population of interest is individuals with osteochondral lesions.

### *Interventions*

The therapy being considered is platelet-rich plasma injections. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### *Comparators*

Comparators of interest include nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, anti-inflammatory agents, and surgery.

### *Outcomes*

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections as a treatment for osteochondral lesions has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 28 weeks of follow-up is considered necessary to demonstrate efficacy.

## Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

### Comparative Studies

No high-quality RCTs on the treatment of osteochondral lesions were identified. Mei-Dan et al (2012) reported on a quasi-randomized study of 29 patients with 30 osteochondral lesions of the talus assigned to 3 intra-articular injections of hyaluronic acid or platelet-rich plasma.<sup>17</sup> At 28-week follow-up, scores on the AOFAS Ankle-Hindfoot Scale improved to a greater extent in the platelet-rich plasma group (from 68 to 92) than in the hyaluronic acid group (from 66 to 78) ( $p < .05$ ). Subjective

global function also improved to a greater extent in the platelet-rich plasma group (from 58 to 91) than in the hyaluronic acid group (from 56 to 73). Interpretation of the composite measures of VAS scores for pain and function is limited by differences between the groups at baseline. Also, neither the patients nor the evaluators were blinded to treatment in this small study.

### **Section Summary: Platelet-Rich Plasma as a Primary Treatment of Osteochondral Lesions**

A single quasi-randomized study has evaluated the efficacy of platelet-rich plasma injections in individuals who have osteochondral lesions. Compared with hyaluronic acid, treatment with platelet-rich plasma resulted in statistically significant improvements in AOFAS Ankle-Hindfoot Scale scores and global function, indicating improved outcomes. Adequately powered and blinded RCTs are required to confirm these findings.

### **Platelet-Rich Plasma as a Primary Treatment of Knee or Hip Osteoarthritis**

#### **Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, anti-inflammatory agents, and surgery, in individuals with knee or hip osteoarthritis.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with knee or hip osteoarthritis.

#### ***Interventions***

The therapy being considered is platelet-rich plasma injections. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

#### ***Comparators***

Comparators of interest include nonpharmacologic therapy (e.g., exercise, physical therapy), analgesics, anti-inflammatory agents, and surgery.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections as a treatment for knee or hip osteoarthritis has varying lengths of follow-up, ranging from 6 to 12 months. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 12 months of follow-up is considered necessary to demonstrate efficacy.

#### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

A number of RCTs and several systematic reviews of RCTs evaluating the use of platelet-rich plasma for knee osteoarthritis have been published.<sup>18,19,20,21,22,23,24,25,26,10</sup> Protocols used in platelet-rich plasma interventions for knee osteoarthritis varied widely. For example, in the studies identified in the Laudy et al (2015) systematic review, platelet-rich plasma was prepared using single, double, or triple spinning techniques, and interventions included between 1 and 3 injections delivered 1 to 3 weeks apart.<sup>20</sup>

## Systematic Reviews

In individuals with knee osteoarthritis undergoing platelet-rich plasma injections, findings from 6 systematic reviews are reported.<sup>18,19,10,27,20,21</sup> A crosswalk of RCTs included in these systematic reviews is found in the Appendix (Table A2); the systematic review by Anil et al (2021) did not delineate which of its included studies evaluated platelet-rich plasma, therefore, is not included in Table A2. The systematic reviews have varied in their outcomes of interest and their findings. Systematic reviews have generally found that platelet-rich plasma was more effective than placebo or hyaluronic acid in reducing pain and improving function. However, systematic review authors have noted that their findings should be interpreted with caution due to important limitations including significant residual statistical heterogeneity, questionable clinical significance, and high risk of bias in study conduct.

Anil et al (2021) published a systematic review with network meta-analysis to compare the efficacy of nonoperative injectable treatments for knee osteoarthritis (see Tables 7 and 8).<sup>18</sup> A total of 79 RCTs (N=8761) were included and the follow-up ranged from 4 weeks to 24 months. Intra-articular injectable treatments included platelet-rich plasma, autologous conditioned serum, bone marrow aspirate concentrate, botulinum toxin, corticosteroids, hyaluronic acid, mesenchymal stem cells, ozone, saline placebo, plasma rich in growth factor, and stromal vascular fraction; the publication did not delineate the number of RCTs that specifically evaluated on platelet-rich plasma. At 12 months, the treatment with the highest P-Score for the MD in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scale score and VAS score was stromal vascular fraction. However, the MD in WOMAC scale and VAS scores for leukocyte-poor platelet-rich plasma and leukocyte-rich platelet-rich plasma versus saline placebo at 12 months did not reach statistical significance.

Trams et al (2020) published a systematic review that included 38 RCTs (N=2962) evaluating the effects of platelet-rich plasma on patients with knee osteoarthritis (see Tables 7 and 8).<sup>19</sup> The meta-analysis focused on the review of 33 blinded studies. Follow-up ranged from 6 months to 2 years. Comparators included hyaluronic acid in 23 studies, placebo (e.g., saline, no injection, physical therapy) in 10 studies, corticosteroids in 4 studies, and acetaminophen in 2 studies. Twenty-two studies reported VAS pain outcomes for placebo (n=5), hyaluronic acid (n=15), and corticosteroids (n=2). Placebo and hyaluronic acid subgroups showed significant VAS differences in favor of platelet-rich plasma ( $p<.00001$ ). The corticosteroid subgroup was not significantly different from platelet-rich plasma ( $p=.23$ ). Six studies comparing single versus multiple injections of platelet-rich plasma showed a significant difference in favor of 3 platelet-rich plasma injections ( $p<.00001$ ). Functional outcomes were reported via the WOMAC scale for placebo (n=9), corticosteroids (n=1), and hyaluronic acid (n=15). Both pooled and subgroup analyses favored platelet-rich plasma ( $p<.00001$ ). In 5 studies assessing multiple versus single platelet-rich plasma injections, significant differences in favor of multiple injections were found ( $p<.00001$ ). Functional outcomes assessed via International Knee Documentation Committee (IKDC) scores were reported in 2 placebo studies and 5 hyaluronic acid studies. While a significant difference was found for hyaluronic acid ( $p=.004$ ), no significant difference was found for placebo ( $p=.24$ ). Pooled estimates for 6 studies comparing platelet-rich plasma to corticosteroids, hyaluronic acid, or mesenchymal stem cells found no significant differences in Knee injury and Osteoarthritis Outcome Score (KOOS) sport, quality of life, activities of daily living, symptoms, or pain subscales. The pooled estimates for adverse events showed non-significant differences in favor of the control groups ( $p=.15$ ). The risk of bias was assessed using Cochrane criteria. One study was at high risk of bias for 3 domains, 2 studies were at high risk of bias

for 2 domains, and 12 studies were at high risk of bias for 1 domain. The most impacted domains were performance bias and reporting bias.

Johal et al (2019) conducted a systematic review and meta-analysis of RCTs comparing platelet-rich plasma with hyaluronic acid (8 trials, n=927), placebo (2 trials, n=105), no platelet-rich plasma (2 trials, n=123), acetaminophen (1 trial, n=75), or a corticosteroid (1 trial, n=48).<sup>10</sup> Meta-analysis of VAS pain scores showed that platelet-rich plasma was more effective than its comparators at 12 months (standard MD, -0.91; 95% CI, -1.41 to -0.41). However, the systematic review authors noted that important limitations of this finding included lack of a clinically significant difference (i.e., less than the effect size threshold of 0.5 for a clinically important difference), high residual statistical heterogeneity between studies ( $\rho=89\%$ ), and high risk of bias in study conduct.

Xu et al (2017) conducted a systematic review and meta-analysis of RCTs comparing platelet-rich plasma with hyaluronic acid (8 trials), or placebo (2 trials), for the treatment of knee osteoarthritis (see Tables 7 and 8).<sup>27</sup> Risk of bias was assessed using Cochrane criteria. Four studies were assessed as being of low-quality, 3 as moderate-quality, and 3 as high-quality. Meta-analyses including 7 of the trials comparing platelet-rich plasma with hyaluronic acid showed that platelet-rich plasma significantly improved the WOMAC or IKDC scores compared with hyaluronic acid at 6-month follow-up; however, when meta-analyses included only the 2 high-quality RCTs, there was not a significant difference between platelet-rich plasma and hyaluronic acid (see Table 8). Also, note that the WOMAC evaluates 3 domains: pain, scored from 0 to 20; stiffness, scored from 0 to 8; and physical function, scored from 0 to 68. Higher scores represent greater pain and stiffness as well as worsened physical capability. The IKDC is a patient-reported, knee-specific outcome measure that measures pain and functional activity. In the meta-analysis comparing platelet-rich plasma with placebo, a third trial was included, which had 4 treatment groups, 2 of which were platelet-rich plasma and placebo. This analysis showed that platelet-rich plasma significantly improved the WOMAC or IKDC scores compared with placebo; however, only 1 of the trials was considered high-quality and that trial only enrolled 30 patients. All meta-analyses showed high heterogeneity among trials ( $\rho \geq 90\%$ ).

Laudy et al (2015) conducted a systematic review of RCTs and nonrandomized clinical trials to evaluate the effect of platelet-rich plasma on patients with knee osteoarthritis (see Tables 7 and 8).<sup>20</sup> Ten trials (N=1110) were selected. Cochrane criteria for risk of bias were used to assess study quality, with 1 trial rated as having a moderate-risk of bias and the remaining 9 trials as high-risk of bias. While meta-analyses showed that platelet-rich plasma was more effective than placebo or hyaluronic acid in reducing pain and improving function (see Table 8), larger randomized studies with a lower risk of bias are needed to confirm these results.

Chang et al (2014) published a systematic review that included 5 RCTs, 3 quasi-randomized controlled studies, and 8 single-arm prospective series (N=1543) (see Tables 7 and 8).<sup>21</sup> The Jadad scale was used to assess RCTs, and the Newcastle-Ottawa Scale was used to assess the other studies; however, results of the quality assessments were not reported. Meta-analysis of functional outcomes at 6 months found that the effectiveness of platelet-rich plasma (effect size, 1.5; 95% CI, 1.0 to 2.1) was greater than that of hyaluronic acid (effect size, 0.7; 95% CI, 0.6 to 0.9; when only RCTs were included). However, there was no significant difference at 12-month follow-up between platelet-rich plasma (effect size, 0.9; 95% CI, 0.5 to 1.3) and hyaluronic acid (effect size, 0.9; 95% CI, 0.5 to 1.2; when only RCTs were included). Fewer than 3 injections, single spinning, and lack of additional activators led to greater uncertainty in the treatment effects. Platelet-rich plasma also had lower efficacy in patients with higher degrees of cartilage degeneration. Results were consistent when analyzing only RCTs but asymmetry in funnel plots suggested significant publication bias.

**Table 7. Systematic Review Characteristics for Knee Osteoarthritis**

Study	Search Date	Trials	Participants	Design
Anil et al (2021) <sup>18</sup>	Through 2020	RCTs of patients receiving PRP, autologous conditioned	Patients with knee OA	79 RCTs

Study	Search Date	Trials	Participants	Design
		serum, bone marrow aspirate concentrate, botulinum toxin, corticosteroids, hyaluronic acid, mesenchymal stem cells, ozone, saline placebo, plasma rich in growth factor, or stromal vascular fraction		
Trams et al (2020) <sup>19</sup>	2005-2020	-10 PRP vs. placebo -23 PRP vs. HA -4 PRP vs. corticosteroid -2 PRP vs. acetaminophen -6 PRP, single vs. multiple injections	Patients with knee OA	38 RCTs
Johal et al (2019) <sup>10</sup>	Through Feb 2017	-8 PRP vs. HA -2 PRP vs. placebo -2 PRP vs. no PRP -1 PRP vs. corticosteroid -1 PRP vs. acetaminophen	Patients with knee OA	14 RCTs
Xu et al (2017) <sup>27</sup>	Through May 2016	-8 PRP vs. HA -2 PRP vs. placebo	Patients with knee OA	10 RCTs
Laudy et al (2015) <sup>20</sup>	Through Jun 2014	- 8 PRP vs. HA -1 PRP vs. placebo - 1 PRP, different preparations	Patients with knee OA	6 RCTs; 4 nonrandomized
Chang et al (2014) <sup>21</sup>	Through Sep 2013	-6 PRP vs. HA -1 PRP vs. placebo -1 PRP, different preparations -8 single-arm PRP	Patients with knee OA	5 RCTs; 3 quasi-randomized; 8 single-arm

HA: hyaluronic acid; OA: osteoarthritis; PRP: platelet-rich plasma; RCT: randomized controlled trial.

**Table 8. Systematic Review Functional Score Results for Knee Osteoarthritis**

Study	Change in Functional Scores (95% CI) <sup>a</sup>	
	6 Months to 2 Years	
Anil et al (2021) <sup>18</sup>	WOMAC at 1 year: Leukocyte-poor PRP vs. saline placebo, -7.65 (-27.18 to 11.88); Leukocyte-rich PRP vs. saline placebo, -13.28 (-28.74 to 2.18)	
Trams et al (2020) <sup>19</sup>	WOMAC: All trials, -12.10 (-14.12 to -7.24); PRP vs. placebo, -14.56 (-21.17 to -7.96); PRP vs. steroid, -16.10 (-19.61 to -12.59); PRP vs. HA, -10.68 (-14.12 to -7.24) IKDC: All trials, 6.94 (2.53 to 11.34); PRP vs. placebo, 8.96 (-5.88 to 23.81); PRP vs. HA, 6.58 (2.12 to 11.05) KOOS - ADL: All trials, 1.23 (-4.85 to 7.31)	
Xu et al (2017) <sup>27</sup>	6 Months PRP vs. HA: All trials: -0.9 (-1.4 to -0.3); Low quality: -13.3 (-33.9 to 3.7); Moderate quality: -1.3 (-1.6 to -1.0); High quality: -0.1 (-0.3 to 0.1) PRP vs. placebo: All trials (3): -2.1 (-3.3 to -1.0)	12 Months NR
Laudy et al (2015) <sup>20</sup>	PRP vs. HA: -0.8 (-1.0 to -0.6)	PRP vs. HA: -1.3 (-1.8 to -0.9)
Chang et al (2014) <sup>21</sup>	PRP, baseline vs. post-treatment: All studies: 2.5 (1.9 to 3.1); Single-arm: 3.1 (2.0 to 4.1); Quasi-randomized: 3.1 (1.4 to 3.8); RCT: 1.5 (1.0 to 2.1)	PRP, baseline vs. posttreatment: All studies: 2.9 (1.0 to 4.8); Single-arm: 2.6 (-0.4 to 5.7); Quasi-randomized: 4.5 (4.1 to 5.0); RCT: 0.9 (0.5 to 1.3)

ADL: activities of daily living; CI: confidence interval; HA: hyaluronic acid; IKDC: International Knee Documentation Committee; KOOS: Knee Injury and Osteoarthritic Outcome Score; NR: not reported; PRP: platelet-rich plasma; RCT: randomized controlled trial; WOMAC: Western Ontario McMaster Osteoarthritis Index.

<sup>a</sup> Functional outcomes were measured by the IKDC, KOOS, or WOMAC.

In individuals with hip osteoarthritis undergoing platelet-rich plasma injections, findings from 2 systematic reviews are reported. Belk et al (2022) identified 6 RCTs comparing the efficacy of platelet-rich plasma (n=211) and hyaluronic acid injections (n=197).<sup>28</sup> The mean follow-up was

approximately 12 months. In an analysis of 4 RCTs, platelet-rich plasma and hyaluronic acid groups had similar improvements in VAS score (MD, 5.9; 95% CI, -0.74 to 1.92) and WOMAC score (MD, 0.27; 95% CI, -0.05 to 0.59). Gazendam et al (2020) identified 11 RCTs (N=1353) assessing the efficacy of platelet-rich plasma, corticosteroids, and saline injections.<sup>29</sup> Pooled pain and functional outcomes were reported for 2 to 4 and 6 months follow-up. No intervention significantly outperformed saline intra-articular injection at any time point. Clinically significant improvements in pain from baseline were observed for all treatment groups, including placebo.

### Randomized Controlled Trials

In individuals with knee osteoarthritis undergoing platelet-rich plasma injections, 3 RCTs with a follow-up of at least 12 months have been published subsequent to several of the above-described systematic reviews (Tables 9 to 12).<sup>30,31,32</sup> All trials were conducted outside of the United States. Sample sizes ranged from 40 to 200 patients. Comparator treatments included corticosteroids, celecoxib, or hyaluronic acid. Two RCTs found statistically significantly greater 1-year reductions in pain and function scores with platelet-rich plasma versus corticosteroids or celecoxib. Sdeek et al (2021) reported on the results of a 36-month RCT that compared 3 intraarticular injections of either platelet-rich plasma (n=95) or hyaluronic acid (n=94) in patients with knee osteoarthritis.<sup>30</sup> Both platelet-rich plasma and hyaluronic acid were effective in improving pain and functional status. Statistical analyses were not performed, however, trends for pain and function scores showed greater improvement in the group that received platelet-rich plasma. The findings of these RCTs should be interpreted with caution due to important study conduct limitations, including potential inadequate control for selection bias and limited or unclear blinding. No significant differences in pain or function scores were observed within the first month of treatment in either study.

Dallari et al (2016) reported on results of an RCT that compared platelet-rich plasma with hyaluronic acid alone or with a combination platelet-rich plasma plus hyaluronic acid in 111 patients with hip osteoarthritis.<sup>33</sup> Although this well-conducted RCT reported positive results, with statistically significant reductions in VAS score (lower scores imply less pain) at 6 months in the platelet-rich plasma arm (21; 95% CI, 15 to 28) versus the hyaluronic acid arm (35; 95% CI, 26 to 45) or the platelet-rich plasma plus hyaluronic acid arm (44; 95% CI, 36 to 52), the impact of treatment on other secondary outcome measures such as Harris Hip Score and the WOMAC scores was not observed. Notably, there was no control for type I error for multiple group comparisons at different time points, and the trial design did not incorporate a sham-control arm. Nouri et al (2022) also conducted an RCT comparing platelet-rich plasma with hyaluronic acid in patients with hip osteoarthritis.<sup>34</sup> A total of 105 patients were randomized to platelet-rich plasma, hyaluronic acid, or the combination. There were no differences in VAS scores between groups at 6 months; however, functional outcomes were improved in the platelet-rich plasma groups compared with hyaluronic acid alone.

**Table 9. Summary of Key RCT Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions		Comparator
					Active	Comparator 1	Comparator 2
Nouri et al (2022) <sup>34</sup>	Iran	1	2019- 2020	Patients with hip OA, grade II to III	PRP (n=35); 2 x 5 mL 14 days apart	HA (n=35); 2 x 2.5 mL 14 days apart	HA + PRP (n=35); 2 x 5 mL PRP + 2.5 mL HA 14 days apart
Sdeek et al (2021) <sup>30</sup>	Egypt	NR	2016- 2020	Patients with knee OA, grade II to III	PRP (n=95); 3 x 2.5 mL 14 days apart	HA (n=94); 3 x 2.5 mL 14 days apart	
Reyes-Sosa et al (2020) <sup>31</sup>	Mexico	1	NR	Patients with knee OA, grade II to III, who were previously treated with acetaminophen	Activated PRP (n=30); 2 x 3 mL 15 days apart	NSAID: (n=30); 200 mg celecoxib every 24 hours for 1 year	

Study	Countries	Sites	Dates	Participants	Interventions	Comparator
Elksnins-Finogejevs et al (2020) <sup>32</sup>	Latvia	1	2016 - 2017	Patients with knee OA, grade II to III without improvement	PRP (n=20); 8 mL single-dose	CS (n=20); 1 mL 40 mg/mL triamcinolone + 5 mL 2% lidocaine
Dallari et al (2016) <sup>33</sup>	Italy	NR	2010 - 2011	Patients with hip OA	PRP (n=44)	PRP+HA (n=31) HA (n=36)

CS: corticosteroid; HA: hyaluronic acid; NR: not reported; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis; PRP: platelet-rich plasma; RCT: randomized controlled trial.

**Table 10. Summary of Key RCT Results**

Study	Pain Outcomes	Functional Outcomes
Knee OA		
Sdeek et al (2021) <sup>30</sup>	Mean VAS Score Baseline: 57.8 12 months: 47.1 36 months: 40.9	Mean IKDC and WOMAC Scores IKDC: Baseline: 49.1 12 months: 67.9 36 months: 55.2
PRP		WOMAC: Baseline: 66.5 12 months: 52.8 36 months: 60.6
HA	Baseline: 59.3 12 months: 50.3 36 months: 60.3	IKDC: Baseline: 47.3 12 months: 61.6 36 months: 46.1
		WOMAC: Baseline: 66.9 12 months: 54.9 36 months: 64.2
Reyes-Sosa et al (2020) <sup>31</sup>	Change in VAS Score from Baseline at 12 mo, % -68.69 (p<.001)	Change in WOMAC Score from Baseline at 12 mo -11.5 <sup>a</sup>
Celecoxib	-40.94 (p<.001)	-4 <sup>a</sup>
P-value for Difference	p<.001	p<.001
Elksnins-Finogejevs et al (2020) <sup>32</sup>	Mean VAS Score (95% CI) Baseline: 6.1 (5.4 to 6.6) 30 weeks: 1.6 (0.7 to 2.6) 58 weeks: 2.9 (2.2 to 3.6)	Mean IKDC Score (95% CI) Baseline: 36.3 (31.2 to 41.4) 30 weeks: 77.5 (70.6 to 84.3) 58 weeks: 62.0 (54.5 to 69.6)
CS	Baseline: 6.0 (5.2 to 6.8) 30 weeks: 4.0 (3.2 to 4.8) 58 weeks: 5.1 (4.1 to 6.0)	Baseline: 28.0 (24.6 to 33.1) 30 weeks: 56.3 (47.4 to 65.3) 58 weeks: 39.8 (32.8 to 46.8)
Hip OA		
Nouri et al (2022) <sup>34</sup>	VAS at 6 mo 3.13 ± 1.29	WOMAC at 6 mo 21.53 ± 10.40
PRP	3.90 ± 1.40	27.21 ± 9.25
HA	3.13 ± 1.18	21.16 ± 8.00
PRP + HA	VAS Score at 6 mo 21	NR
Dallari et al (2016) <sup>35</sup>	35	
PRP	44	

CI: confidence interval; CS: corticosteroids; HA: hyaluronic acid; IKDC: International Knee Documentation Score; NR: not reported; OA: osteoarthritis; PRP: platelet-rich plasma; RCT: randomized controlled trial; VAS: visual analog scale; WOMAC: Western Ontario and McMaster

Universities Osteoarthritis Index.

<sup>a</sup>Calculated estimate.

**Table 11. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow Up <sup>e</sup>
Nouri et al (2022) <sup>34</sup>					1. Only 6 months follow-up
Sdeek et al (2021) <sup>30</sup>					
Reyes-Sosa et al (2020) <sup>31</sup>			3. Unclear adherence to treatment.	5. Clinically significant difference not defined.	
Elksnins-Finogejevs et al (2020) <sup>32</sup>					
Dallari et al (2016) <sup>33</sup>					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup>Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup>Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

<sup>c</sup>Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup>Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup>Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 12. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Binding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow Up <sup>d</sup>	Statistical <sup>f</sup>
Nouri et al (2022) <sup>34</sup>		1. Patients not fully blind due to differences in administration procedures			
Sdeek et al (2021) <sup>30</sup>				1. Power calculations not reported; 2. and/or p Power not calculated for primary outcome	3. Confidence intervals not reported; 4. Comparative treatment effects not calculated.
Reyes-Sosa et al (2020) <sup>31</sup>	2. Allocation not concealed from patients or health care providers.	1-3. Blinding of outcome assessors not clear.	1. Not registered.	1. Power not calculated.	2. Confidence intervals not reported.
Elksnins-Finogejevs et al (2020) <sup>32</sup>	2. Allocation not concealed from patients or health care providers.	1-3. Not double-blinded.			

Study	Allocation <sup>a</sup>	Binding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow Up <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Dallari et al (2016) <sup>33</sup>	2. Allocation not concealed from patients or health care providers	1. Only data collectors and outcome assessors blinded to treatment assignment				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

## Section Summary: Platelet-Rich Plasma as a Primary Treatment of Knee or Hip Osteoarthritis

Multiple RCTs and systematic reviews with meta-analysis have evaluated the efficacy of platelet-rich plasma injections in individuals with knee or hip osteoarthritis. Most trials have compared platelet-rich plasma with hyaluronic acid for knee osteoarthritis. A single RCT compared platelet-rich plasma with hyaluronic acid alone or combination platelet-rich plasma plus hyaluronic acid in hip osteoarthritis. Systematic reviews have generally found that platelet-rich plasma was more effective than placebo or hyaluronic acid in reducing pain and improving function. However, systematic review authors have noted that their findings should be interpreted with caution due to important limitations including significant residual statistical heterogeneity, questionable clinical significance, and high risk of bias in study conduct. RCTs with follow-up durations of at least 12 months published subsequent to the systematic reviews found statistically significantly greater 12-month reductions in pain and function outcomes, but these findings were also limited by important study conduct flaws including potential inadequate control for selection bias and limited or unclear blinding. Also, benefits were not maintained at 5 years. Using hyaluronic acid as a comparator is questionable because the evidence demonstrating the benefit of hyaluronic acid treatment for osteoarthritis is not robust. Two systematic reviews evaluating hip osteoarthritis did not report any statistically or clinically significant differences in pain or functional outcomes compared to hyaluronic acid, corticosteroids, or placebo. Additional larger controlled studies comparing platelet-rich plasma with placebo and alternatives other than hyaluronic acid are needed to determine the efficacy of platelet-rich plasma for knee and hip osteoarthritis. Further studies are also needed to determine the optimal protocol for delivering platelet-rich plasma.

## Platelet-Rich Plasma as an Adjunct to Surgery

### Anterior Cruciate Ligament Reconstruction

#### Clinical Context and Therapy Purpose

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with anterior cruciate ligament (ACL) reconstruction.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with ACL reconstruction.

### ***Interventions***

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### ***Comparators***

Comparators of interest include orthopedic surgery alone.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for ACL reconstruction has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 2 years of follow-up is considered necessary to demonstrate efficacy.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Systematic Reviews**

A Cochrane review by Moraes et al (2014) on platelet-rich therapies for musculoskeletal soft tissue injuries identified 2 RCTs and 2 quasi-randomized studies (N=203) specifically on platelet-rich plasma used in conjunction with ACL reconstruction.<sup>36</sup> Pooled data found no significant difference in IKDC scores between the platelet-rich plasma and control groups.

A systematic review and meta-analysis by Trams et al (2020) identified 16 RCTs (N=740).<sup>19</sup> Five studies showed no significant overall difference with respect to pain ( $p=.43$ ). In 4 studies reporting IKDC scores, no significant differences were noted ( $p=.83$ ). In 4 studies, no significant differences in functional outcomes as measured by the Lysholm score were reported ( $p=.19$ ). Pooled estimates for Tegner scale activity assessments in 5 studies showed no significant differences ( $p=.38$ ) in favor of the control. Twelve studies were deemed to be at high risk of bias in at least 1 domain.

A systematic review and meta-analysis by Lv et al (2022) identified 17 RCTs (N=970) in patients undergoing ACL reconstruction.<sup>37</sup> Compared to controls, platelet-rich plasma improved VAS score (MD, -1.12; 95% CI, -1.92 to -0.31;  $p=.007$ ), Lysholm score (MD, 8.49; 95% CI, 1.63 to 15.36) and subjective IKDC score (MD, 6.08; 95% CI, 4.39 to 7.77;  $p<.00001$ ) at 6 months. The authors only considered the difference in pain score to be clinically relevant, and they did not consider any differences between groups at 12 months to be clinically meaningful (VAS MD, -0.47 and subjective IKDC score MD, 3.99). Overall, the evidence was determined to be of moderate quality.

### **Randomized Controlled Trials**

An RCT reported by Nin et al (2009), randomized 100 patients to arthroscopic ACL reconstruction with or without platelet-rich plasma.<sup>38</sup> The use of platelet-rich plasma on the graft and inside the tibial tunnel in patients treated with bone-patellar tendon-bone allografts had no discernable clinical or biomechanical effect at 2-year follow-up.

Ye et al (2024) randomized 120 patients undergoing ACL reconstruction 1:1 to receive either postoperative platelet-rich plasma at monthly intervals for 3 months or no postoperative injection.<sup>39</sup> At 12 months, there were no significant differences in function or symptoms based on KOOS score between groups.

### **Retrospective Cohort Studies**

Bailey et al (2021) reported on a retrospective matched case-control study evaluating the effects of intraoperative platelet-rich plasma on postoperative knee function and complications at 2 years after ACL reconstruction with meniscal repair.<sup>40</sup> The study was conducted between 2013 and 2017 and included 162 patients who received platelet-rich plasma and 162 patients who did not. Results demonstrated that there were no differences in knee function scores between the platelet-rich plasma and matched-control groups at 2 years, as well as no differences in the timing of return to activity (mean, 7.8 vs. 8.0 months;  $p=.765$ ). However, the platelet-rich plasma group demonstrated a higher rate of postoperative knee motion loss compared with the control group (13.6% vs. 4.6%;  $p<.001$ ).

### **Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment of Anterior Cruciate Ligament Reconstruction**

Several systematic reviews that included multiple RCTs, quasi-randomized studies, and/or prospective studies have evaluated the efficacy of platelet-rich plasma injections in individuals undergoing ACL reconstruction. Three systematic reviews conducted a meta-analysis. Two showed that adjunctive platelet-rich plasma treatment did not result in a significant effect on function and activity outcomes, including IKDC score. One systematic review did find statistically significant benefit with platelet-rich plasma compared with control in terms of VAS, Lysholm score, and IKDC at 6 months; however, the authors only considered the differences in pain scores to be clinically relevant. By 12 months, none of the differences between groups were clinically relevant. Individual studies have shown mixed results. A retrospective matched case-control study found no differences in knee function scores or time to return of activity between platelet-rich plasma and matched-control groups at 2 years; however, the platelet-rich plasma group demonstrated a higher rate of postoperative knee motion loss compared with the control group (13.6% vs 4.6%).

## **Hip Fracture**

### **Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with hip fracture.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with hip fracture.

### ***Interventions***

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### ***Comparators***

Comparators of interest include orthopedic surgery alone.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for hip fracture has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Randomized Controlled Trials**

One RCT was identified for the treatment of a hip fracture with platelet-rich plasma. Griffin et al (2013) reported on a single-blind randomized trial assessing the use of platelet-rich plasma for the treatment of hip fractures in patients ages 65 years and older.<sup>41</sup> Patients underwent internal fixation of a hip fracture with cannulated screws and were randomized to standard-of-care fixation (n=99) or standard-of-care fixation plus injection of platelet-rich plasma into the fracture site (n=101). The primary outcome measure was the failure of fixation within 12 months, defined as any revision surgery. The overall risk of revision by 12 months was 36.9%, and the risk of death was 21.5%. There was no significant risk reduction (39.7% control vs. 34.1% platelet-rich plasma; absolute risk reduction, 5.6%; 95% CI, -10.6% to 21.8%) or significant difference between groups for most of the secondary outcome measures. For example, mortality was 23% in the control group and 20% in the platelet-rich plasma group. The length of stay was significantly reduced in the platelet-rich plasma-treated group (median difference, 8 days). For this measure, there is a potential for bias from the nonblinded treating physician.

#### **Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Hip Fracture**

A single open-label RCT has evaluated the efficacy of platelet-rich plasma injections in individuals with a hip fracture. This trial failed to show any statistically significant reductions in the need for revision surgery after platelet-rich plasma treatment.

### **Long Bone Nonunion**

#### **Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as recombinant human bone morphogenetic protein-7 (rhBMP-7) plus orthopedic surgery, in individuals with long bone nonunion.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with long bone nonunion.

### ***Interventions***

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### ***Comparators***

Comparators of interest include rhBMP-7 plus orthopedic surgery.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for long bone nonunion has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Systematic Reviews**

A Cochrane review by Griffin et al (2012) found only 1 small RCT (N=21) evaluating platelet-rich plasma for long bone healing.<sup>42</sup> However, because only studies comparing platelet-rich plasma with no additional treatment or placebo were eligible for inclusion, reviewers did not select a larger RCT by Calori et al (2008; discussed below).<sup>43</sup>

#### **Randomized Controlled Trials**

The trial by Dallari et al (2007), which was included in the Cochrane review, compared platelet-rich plasma plus allogenic bone graft with allogenic bone graft alone in patients undergoing corrective osteotomy for medial compartment osteoarthritis of the knee.<sup>35</sup> According to Cochrane reviewers, the risk of bias in this study was substantial. Results showed no significant differences in patient-reported or clinician-assessed functional outcome scores between groups at 1 year. However, the proportion of bones united at 1 year was statistically significantly higher in the platelet-rich plasma plus allogenic bone graft arm (8/9) compared with the allogenic bone graft alone arm (3/9; relative risk [RR], 2.67; 95% CI, 1.03 to 6.91). This benefit, however, was not statistically significant when assuming poor outcomes for participants who were lost to follow-up (8/11 vs. 3/10; RR, 2.42; 95% CI, 0.88 to 6.68). Tables 13 and 14 describe this RCT and the subsequent RCT's characteristics and results, respectively. Tables 15 and 16 describe study design and conduct limitations.

Calori et al (2008) compared the application of platelet-rich plasma with rhBMP-7 for the treatment of long bone nonunions in an RCT involving 120 patients and 10 surgeons.<sup>43</sup> Inclusion criteria were posttraumatic atrophic nonunion for at least 9 months, with no signs of healing over the last 3 months, and considered as treatable only by means of fixation revision. Autologous bone graft had been used in a prior surgery in 23 cases in the rhBMP-7 group and 21 cases in the platelet-rich plasma group. Computer-generated randomization created 2 homogeneous groups; there were generally similar numbers of tibial, femoral, humeral, ulnar, and radial nonunions in the 2 groups. Following

randomization, patients underwent surgery for nonunion, including bone grafts according to the surgeon's choice (66.6% of rhBMP-7 patients, 80% of platelet-rich plasma patients). Clinical and radiologic evaluations by 1 radiologist and 2 surgeons trained in the study protocol revealed fewer unions in the platelet-rich plasma group (68%) than in the rhBMP-7 group (87%). Clinical and radiographic healing times were also found to be slower by 13% to 14% with platelet-rich plasma.

Samuel et al (2017) conducted a controlled trial in which patients with delayed unions (15 to 30 weeks old) were randomized to 2 platelet-rich plasma injections at the fracture site at baseline and 3 weeks (n=23) or no treatment (n=17).<sup>44</sup> The delayed unions were in the tibia (n=29), femur (n=8), forearm (n=2), and the humerus (n=1). The main outcome was long bone union, defined as no pain or tenderness on weight bearing, no abnormal mobility, and bridging at 3 or more cortices in x-ray. Examinations were conducted every 6 weeks for 36 weeks or until union. Percent union did not differ significantly between the 2 groups (78% in the platelet-rich plasma group vs. 59% in the control group). Time to union also did not differ significantly (15.3 weeks for the platelet-rich plasma group vs. 13.1 weeks for the control group).

**Table 13. Summary of Key RCT Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions	Comparator
Dallari et al (2007) <sup>35</sup>	Italy	NR	NR	Patients undergoing high tibial osteotomy to treat genu varum	Implantation of lyophilized bone chips with platelet gel (n=11)	Implantation of lyophilized bone chips with platelet gel and bone marrow stromal cells (n=12)
Calori et al (2008) <sup>43</sup>	Italy	1	2005-2007	Patients undergoing treatment of long bone nonunions	PRP (n=60)	rhBMP-7 (n=60)
Samuel et al (2017) <sup>44</sup>	India	1	2010-2014	Patients with delayed unions	PRP (n=23)	No treatment (n=17)

NR: not reported; PRP: platelet-rich plasma; RCT: randomized controlled trial; rhBMP-7: recombinant human bone morphogenetic protein-7.

**Table 14. Summary of Key RCT Results**

Study	Knee Society Score at 1 yr	Knee Society Functional Score at 1 yr	Union Rate	Median Healing Time
Dallari et al (2007) <sup>35</sup>				
PRP	91.3 ± 2	99.0 ± 0.6		
PRP+bone marrow	89.9 ± 4	99.2 ± 0.5		
Non-PRP	90.3 ± 4	98.8 ± 0.6		
Calori et al (2008) <sup>43</sup>				
PRP			41 (68.3%)	4 ± 0.61 months
rhBMP-7			52 (86.7%)	3.5 ± 0.48
p-value			.016	
Samuel et al (2017) <sup>44</sup>				
PRP			18 (78%)	15.3 weeks
Control			10 (59%)	13.1 weeks
p-value			.296	.54

PRP: platelet-rich plasma; RCT: randomized controlled trial; rhBMP-7: recombinant human bone morphogenetic protein-7.

**Table 15. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow Up <sup>e</sup>
Dallari et al (2007) <sup>35</sup>	3. Only 33 patients included				
Calori et al (2008) <sup>43</sup>					
Samuel et al (2017) <sup>44</sup>					

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

**Table 16. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow Up <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Dallari et al (2007) <sup>35</sup>	3. Allocation concealment unclear	1,2,3. No blinding described			1,2. Study was underpowered and nonparametric statistical tests were performed	
Calori et al (2008) <sup>43</sup>	2. Allocation not concealed	1,2,3. No blinding described				
Samuel et al (2017) <sup>44</sup>	1. Randomization procedure not described, 3. Allocation concealment unclear	1,2,3. No blinding described				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Long Bone Nonunion

Three RCTs have evaluated the efficacy of platelet-rich plasma injections in individuals with long bone nonunion. One trial with a substantial risk of bias failed to show significant differences in patient-reported or clinician-assessed functional outcome scores between patients who received

platelet-rich plasma plus allogenic bone graft versus those who received only allogenic bone graft. While the trial showed statistically significant increases in the proportion of bones that healed in patients receiving platelet-rich plasma in a modified intention-to-treat analysis, the results did not differ in the intention-to-treat analysis. An RCT that compared platelet-rich plasma with rhBMP-7 also failed to show any clinical and radiologic benefits of platelet-rich plasma over rhBMP-7. The third RCT found no difference in the number of unions or time to union in patients receiving platelet-rich plasma injections or no treatment.

### **Rotator Cuff Repair**

#### **Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with rotator cuff repair.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with rotator cuff repair.

#### ***Interventions***

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

#### ***Comparators***

Comparators of interest include orthopedic surgery alone.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for rotator cuff repair has varying lengths of follow-up, ranging from 6 months to 3.5 years. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 3.5 years of follow-up is considered necessary to demonstrate efficacy.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Systematic Reviews**

The literature on platelet-rich plasma for rotator cuff repair consists of several RCTs and systematic reviews that have evaluated the efficacy of platelet-rich plasma membrane or matrix combined with surgical repair of the rotator cuff. A crosswalk of RCTs included in these systematic reviews is found in the Appendix (Table A3). The systematic reviews have varied in their outcomes of interest and findings (Tables 17 and 18).<sup>10,36,45,46,47,48,49</sup> For pain outcomes, systematic reviews generally found

significant reductions with platelet-rich plasma at 12 months.<sup>47,10</sup> However, systematic review authors noted that the pain findings should be interpreted with caution due to significant residual statistical heterogeneity,<sup>47</sup> lack of a clinically significant difference (i.e., less than the effect size threshold of 0.5 for a clinically important difference),<sup>10</sup> and high risk of bias in study conduct.<sup>10,49</sup> Some systematic reviews generally did not show a statistically or clinically significant benefit of platelet-rich plasma on other outcomes, including function, retear rate, and Constant scores.<sup>48</sup> One systematic review found a statistically significant reduction in retear rate in a subgroup analysis of 4 long-term RCTs that were at least 24 months in duration.<sup>49</sup> No reviews have demonstrated a consistent statistically and clinically significant benefit of platelet-rich plasma across multiple outcomes of interest for the 3.5 years of follow-up that is considered necessary to conclusively demonstrate efficacy. The systematic review by Wang et al (2019) reported on adverse effects, and noted that complications were only reported in 1 of the included RCTs, occurring in 5.6% of participants in the platelet-rich plasma groups and none in the control groups. The complications included infection, hematoma, and an exanthematous itchy skin lesion in 1 patient each.

**Table 17. Systematic Reviews & Meta-Analysis Characteristics**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Li et al (2021) <sup>49</sup>	Through Oct 2020	16 (PRP)	Patients undergoing surgery for rotator cuff repair	1440 (28 to 120)	RCT	1.5 to 60 mo
Chen et al (2020) <sup>48</sup>	2011-2017	17	Patients with rotator cuff tears	1116 <sup>a</sup> (36 to 120)	RCT	NR
Johal et al (2019) <sup>10</sup>	2011-2016	13	Patients undergoing surgery for rotator cuff repair	858 (25 to 120)	RCT	7w to 24mo
Chen et al (2018) <sup>47</sup>	2011-2016	37	Patients with tendon and ligament injuries	1031 <sup>a</sup> (NR)	RCT	NR
Fu et al (2017) <sup>50</sup>	2011-2015	11	Patients with rotator cuff injury or tendinopathy	638 (NR)	RCT	NR
Zhao et al (2015) <sup>45</sup>	2011-2013	8	Patients with rotator cuff injury	464 (28 to 88)	RCT	NR
Moraes et al (2014) <sup>36</sup>	2008-2013	19	Patients undergoing rotator cuff repair	1088 (23 to 150)	RCT and quasi-randomized trials	NR

NR: not reported; PRP: platelet-rich plasma; RCT: randomized controlled trial.

<sup>a</sup> Number of participants which could be included in the quantitative analysis.

**Table 18. Systematic Reviews & Meta-Analysis Results**

Study	VAS Reduction	VAS Reduction at 1 Year	Difference in Retear Rate	Difference in Function	Difference in Function at 1 Year
Li et al (2021) <sup>49</sup>	10 RCTs; n=559		12 RCTs; n=700 RCTs $\geq$ 24 months: 4 RCTs, n=255	UCLA Score: 7 RCTs; n=437	
Point estimate	10 RCTs: MD - 0.13		12 RCTs: RR, 0.56 RCTs $\geq$ 24 months: RR, 0.40	7 RCTs: MD, 0.40	
95% CI	10 RCTs: -0.56 to -0.06		12 RCTs: RR, 0.56 RCTs $\geq$ 24 months: 0.22 to 0.73	7 RCTs: MD, 0.86 to 2.24	
Chen et al (2020) <sup>48</sup>		8 RCTs; N=469			UCLA Score: 6 RCTs; N=386
WMD		-0.34			1.39
95% CI		-0.76 to 0.09			0.35 to 2.43
$P$		87.5%			37.8%
Johal et al (2019) <sup>10</sup>		7 RCTs, N=324			

Study	VAS Reduction	VAS Reduction at 1 Year	Difference in Retear Rate	Difference in Function	Difference in Function at 1 Year
SMD		-0.261			
95% CI		-0.46 to -0.05			
p		0%			
Chen et al (2018) <sup>47</sup>					
WMD		-0.84			
95% CI		-1.23 to -0.44			
p-value		<.01			
Fu et al (2017) <sup>50</sup>					
SMD		0.142 <sup>a</sup>			
95% CI		-0.08 to 0.364			
p-value		.209			
Zhao et al (2015) <sup>45</sup>					
RR		0.94			
95% CI		0.70 to 1.25			
p-value		.66			
Moraes et al (2014) <sup>36</sup>					
SMD				0.25	
95% CI				-0.07 to 0.57	
p-value				.12	

<sup>a</sup> Change from baseline at final follow-up. Follow-up durations ranged from 6 weeks to 24 months.

CI: confidence interval; MD: mean difference; RCT: randomized controlled trial; RR: risk ratio; SMD: standard mean difference; UCLA: University of California at Los Angeles (UCLA) activity score; VAS: visual analog scale; WMD: weighted mean difference.

### Randomized Controlled Trials

Data from a 2011 double-blind RCT by Randelli et al that included 53 patients randomized to receive arthroscopic rotator cuff repair with or without the addition of platelet-rich plasma is included in multiple meta-analyses summarized above. Randelli et al (2021) published results of a 10-year follow-up of this trial, which included data for 17 patients who received platelet-rich plasma and 21 control group patients.<sup>51</sup> At the 10-year follow-up, both platelet-rich plasma and control groups experienced improvements in the median (interquartile range [IQR]) University of California at Los Angeles (UCLA) activity score (34 [29 to 35] and 33 [29 to 35] points, respectively) and VAS score (0.34 [0 to 1.85] and 0.70 [0 to 2.45] points, respectively); the between-group differences did not reach statistical significance. Furthermore, approximately 37% of the operated patients had a re-rupture in each group. Retears occurred in 6% of the patients who received platelet-rich plasma treatment and 14% of patients in the control group ( $p=.61$ ).

Rossi et al (2024) examined if the use of platelet-rich plasma as an adjuvant to arthroscopic rotator cuff repair decreased the rate of retears compared with a control group at a single center.<sup>52</sup> Patients with rotator cuff tears <3 cm were enrolled and randomly allocated to rotator cuff repair alone ( $n=48$ ) or rotator cuff repair with a platelet-rich plasma injection during surgery ( $n=48$ ). The rate of retears in the platelet-rich plasma group was 15.2% (95% CI, 6% to 28%), which was lower than the rate of retears in the control group (34.1%; 95% CI, 20% to 49%;  $p=.037$ ). Overall, functional outcomes were improved after surgery across groups and there were no significant differences in functional scores, postoperative pain, and other patient-reported outcomes between groups.

Yao et al (2024) reported on an RCT comparing adjunctive platelet-rich plasma, either leukocyte-rich (LR) or leukocyte-poor (LP), to no injection in patients with rotator cuff tears undergoing arthroscopic repairs.<sup>53</sup> Patients randomized to the platelet-rich plasma groups were administered an injection postoperatively into the tendon-to-bone interface. Functional outcomes were analyzed in 142 individuals (LR platelet-rich plasma  $n=46$ ; LP-platelet-rich plasma  $n=47$ ; control  $n=49$ ). There was no difference in the primary outcome of the UCLA score among the 3 groups ( $p=.169$ ). Additionally, there were no significant differences in other functional outcomes and range of motion between the

groups at 12 months. At 12 months post-surgery, the retear rate was 8% and there were no significant differences in the rates of overall retear ( $p=.755$ ). The only surgical complication reported was postoperative stiffness, which occurred in 3% of patients, and did not differ among groups ( $p=.790$ ).

### **Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Rotator Cuff Repair**

For individuals undergoing rotator cuff repair who receive platelet-rich plasma injections, the evidence includes multiple systematic reviews with meta-analyses and an RCT. Relevant outcomes include symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. Although systematic reviews consistently found significant reductions in pain with platelet-rich plasma at 12 months, important study conduct and relevance weaknesses limit interpretation of these findings. While the systematic reviews and meta-analyses generally failed to show a statistically and/or clinically significant impact on other outcomes, 1 meta-analysis found a statistically significant reduction in retear rate in a subgroup analysis of 4 RCTs that were at least 24 months in duration. Findings of a subsequently published 10-year follow-up of a small RCT failed to demonstrate the superiority of platelet-rich plasma over control for clinical and radiologic outcomes. Two newer RCTs also found no difference in the addition of platelet-rich plasma over control in functional outcomes at either 6 months or 1 year follow-up. The variability in platelet-rich plasma preparation techniques and platelet-rich plasma administration limits the generalizability of the available evidence.

## **Spinal Fusion**

### **Clinical Context and Therapy Purpose**

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with spinal fusion.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with spinal fusion.

#### ***Interventions***

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

#### ***Comparators***

Comparators of interest include orthopedic surgery alone.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for spinal fusion has varying lengths of follow-up.

#### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

### Randomized Controlled Trials

One small (N=62), unblinded, single-center RCT for spinal fusion conducted in Japan and published by Kubota et al (2019) was identified that compared platelet-rich plasma to no platelet-rich plasma.<sup>54</sup> Follow-up was 24 months. Although fusion rates were significantly improved with platelet-rich plasma, there were no significant differences in VAS scores between the 2 groups. Major limitations of this RCT include that patients were unblinded to treatment, and there was no placebo comparator.

### Prospective Cohort Studies

Two prospective observational studies found no differences in fusion rates with the use of a platelet gel or platelet glue compared with historical controls.<sup>55,56</sup>

### Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Spinal Fusion

For individuals undergoing spinal fusion who receive platelet-rich plasma injections, the evidence includes a single small RCT and a few observational studies. Relevant outcomes include symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. Studies have generally failed to show a statistically and/or clinically significant impact on symptoms (i.e., pain).

## Subacromial Decompression Surgery

### Clinical Context and Therapy Purpose

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with subacromial decompression surgery.

The following PICO was used to select literature to inform this review.

### *Populations*

The relevant population of interest is individuals with subacromial decompression surgery.

### *Interventions*

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### *Comparators*

Comparators of interest include orthopedic surgery alone.

### *Outcomes*

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for subacromial decompression surgery has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

### Randomized Controlled Trials

One small RCT evaluated the use of platelet-rich plasma as an adjunct to subacromial decompression surgery. Evert et al (2008) reported on a rigorously conducted, small (N=40), double-blinded RCT of platelet and leukocyte-rich plasma gel following open subacromial decompression surgery in a carefully selected patient population.<sup>57</sup> Neither self-assessed nor physician-assessed instability improved. Both subjective pain and use of pain medication were lower in the platelet and leukocyte-rich plasma group across the 6 weeks of measurements. For example, at 2 weeks after surgery, VAS scores for pain were lower by about 50% in the platelet and leukocyte-rich plasma group (close to 4 in the control group, close to 2 in the platelet and leukocyte-rich plasma group), and only 1 (5%) patient in the platelet and leukocyte-rich plasma group was taking pain medication compared with 10 (50%) control patients. Objective measures of range of motion showed clinically significant improvements in the platelet and leukocyte-rich plasma group across the 6-week assessment period, with patients reporting improvements in activities of daily living, such as the ability to sleep on the operated shoulder at 4 weeks after surgery and earlier return to work.

### Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Subacromial Decompression Surgery

A single small RCT has evaluated the efficacy of platelet-rich plasma injections in individuals undergoing subacromial decompression surgery. Compared with controls, platelet-rich plasma treatment did not improve self-assessed or physician-assessed instability. However, subjective pain, use of pain medication, and objective measures of range of motion showed clinically significant improvements with platelet-rich plasma. Larger RCTs would be required to confirm these benefits.

## Total Knee Arthroplasty

### Clinical Context and Therapy Purpose

The purpose of platelet-rich plasma injections plus orthopedic surgery is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as orthopedic surgery alone, in individuals with total knee arthroplasty.

The following PICO was used to select literature to inform this review.

### *Populations*

The relevant population of interest is individuals with total knee arthroplasty.

### *Interventions*

The therapy being considered is platelet-rich plasma injections plus orthopedic surgery. The use of platelet-rich plasma has been proposed as a treatment for various musculoskeletal conditions and as an adjunctive procedure in orthopedic surgeries. The potential benefit of platelet-rich plasma has received considerable interest due to the appeal of a simple, safe, low-cost, and minimally invasive method of applying growth factors.

### *Comparators*

Comparators of interest include orthopedic surgery alone.

### **Outcomes**

The general outcomes of interest are symptoms, functional outcomes, health status measures, quality of life, morbid events, resource utilization, and treatment-related morbidity. The existing literature evaluating platelet-rich plasma injections plus orthopedic surgery as a treatment for total knee arthroplasty has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- a. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- b. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- c. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- d. Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Systematic Reviews**

Trams et al (2020) published a systematic review and meta-analysis that included 6 RCTs (N=621) evaluating the effects of intraoperative platelet-rich plasma as an adjunct to total knee arthroplasty.<sup>19</sup> Two studies were deemed at high risk of bias. The primary aim of the studies was to assess blood loss during the procedure. While there were significant differences in favor of platelet-rich plasma in the overall effect on blood parameters in comparison to the control groups (standard MD, -0.29; 95% CI, -0.46 to -0.11), no significant differences in range of motion, functional outcomes, or long-term pain were observed.

Shu et al (2022) evaluated platelet-rich plasma in patients undergoing total joint replacement including 8 studies in patients with total knee arthroplasty (1 study for total hip arthroplasty and 1 on total hip or knee arthroplasty).<sup>58</sup> Of the 3 studies reporting VAS scores in patients undergoing total knee arthroplasty (n=161), pain scores were similar during the first 2 postoperative days, but by 3 weeks and 2 months had improved with platelet-rich plasma compared with control (MD, -0.92; 95% CI, -1.25 to -0.60 and -0.93; 95% CI, -1.24 to -0.63, respectively). There were no differences in range of motion, WOMAC scores, length of hospital stay, or wound healing within 4 weeks between platelet-rich plasma or controls in patients undergoing total knee arthroplasty. The authors noted high heterogeneity and the need for more high-quality RCTs.

#### **Subsection Summary: Platelet-Rich Plasma as Adjunctive Treatment for Total Knee Arthroplasty**

Two systematic reviews have evaluated the efficacy of intraoperative platelet-rich plasma in individuals undergoing total knee arthroplasty. In the review by Trams et al (2020) there were no significant differences between the platelet-rich plasma and untreated control groups across several functional and pain outcomes. The systematic review by Shu et al (2022) found improved VAS scores in patients undergoing total knee arthroplasty; however, there were no differences in other outcomes and the authors noted high heterogeneity and the need for well-designed RCTs.

### **Supplemental Information**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to

guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American Academy of Orthopaedic Surgeons

In 2021, the American Academy of Orthopaedic Surgeons (AAOS) guidelines for the management of osteoarthritis of the knee made the following recommendation:<sup>59</sup>

- "Platelet-rich plasma (PRP) may reduce pain and improve function in patients with symptomatic osteoarthritis of the knee. (Strength of Recommendation: Limited)" The variability of study findings was noted to have contributed to the low strength of recommendation rating.

In 2023, the AAOS updated evidence-based guidelines on the management of osteoarthritis of the hip.<sup>60</sup> In the section on intra-articular injectables, the guidelines gave a moderate recommendation based on high-quality evidence supporting the use of intra-articular corticosteroids as an option to improve function and reduce pain in the short term for patients with osteoarthritis of the hip. There was also a strong recommendation based on high-quality evidence against the use of intra-articular hyaluronic acid, as it does not perform better than placebo in improving function, stiffness, and pain in patients with hip osteoarthritis. The guidelines did not mention any evidence or make recommendations related to the use of platelet-rich plasma for the treatment of osteoarthritis of the hip.

In 2019, the AAOS issued evidence-based guidelines on the management of rotator cuff injuries.<sup>61</sup> The guideline noted the following recommendations related to the use of platelet-rich plasma in this setting:

- "There is limited evidence supporting the routine use of platelet-rich plasma for the treatment of cuff tendinopathy or partial tears (Strength of Recommendation: Limited)." The variability of study findings was noted to have contributed to the low strength of recommendation rating.
- "Strong evidence does not support biological augmentation of rotator cuff repair with platelet-derived products on improving patient reported outcomes; however, limited evidence supports the use of liquid platelet-rich plasma in the context of decreasing re-tear rates (Strength of Recommendation: Strong)."
- "In the absence of reliable evidence, it is the consensus of the work group that we do not recommend the routine use of platelet-rich plasma in the non-operative management of full-thickness rotator cuff tears (Strength of Recommendation: Consensus)."

### National Institute for Health and Care Excellence

In 2013, the NICE issued guidance on the use of autologous blood injection for tendinopathy.<sup>62</sup> The NICE concluded that the current evidence on the safety and efficacy of autologous blood injection for tendinopathy was "inadequate" in quantity and quality.

In 2013, the NICE also issued guidance on the use of autologous blood injection (with or without techniques for producing platelet-rich plasma) for plantar fasciitis.<sup>63</sup> The NICE concluded that the evidence on autologous blood injection for plantar fasciitis raised no major safety concerns but that the evidence on efficacy was "inadequate in quantity and quality."

In 2019, the NICE issued guidance on the use of platelet-rich plasma for osteoarthritis of the knee.<sup>64</sup> The NICE concluded that current evidence on platelet-rich plasma injections for osteoarthritis of the knee raised "no major safety concerns"; however, the "evidence on efficacy is limited in quality." Therefore, NICE recommended that "this procedure should only be used with special arrangements for clinical governance, consent, and audit or research."

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 19.

**Table 19. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT05742061	Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee Osteoarthritis	100	Dec 2023
NCT03734900	Comparison of Effectiveness Between Platelet Lysate and Platelet-rich Plasma on Knee Osteoarthritis: a Prospective, Randomized, Placebo-controlled Trial	150	May 2022
NCT03984955	A Prospective, Double Blind, Single Centre, RCT, Comparing the Effectiveness of Physiotherapy in Addition to One of 3 Types of Image Guided Injection of the Common Extensor Tendon, on Pain and Function in Patients With Tennis Elbow	123	Feb 2026
<i>Unpublished</i>			
NCT04697667	The Combination of Exercise and PRP vs Exercise Alone in Patients With Knee Osteoarthritis: A Randomized Controlled Clinical Trial	84	Feb 2022
NCT01843504	The Clinical, Biomechanical, and Tissue Regenerating Effects of a Single Platelet-rich Plasma Injection for the Treatment of Chronic Patellar Tendinopathy: a Randomized Controlled Trial	29	Feb 2024


NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Appendix 1

**Table A1. Comparison of RCTs Included in SRs & M-As for Treatment of Mixed Tendinopathies**


Study	Masiello (2022) <sup>7</sup>	Dai (2023) <sup>8</sup>	Muthu (2021) <sup>9</sup>	Johal (2019) <sup>10</sup>
<i>Mixed tendinopathy RCTs</i>				
Boesen (2020)	●			
Boesen (2017)	●	●		
Chen (2021)	●			
Dadgostar (2021)	●			
De Jonge (2011)	●			
De Vos (2010)	●	●		
Dragoo (2014)		●		
Fildaro (2012)				
Gogna (2016)	●			
Kesikburun (2013)	●	●		
Kim (2013)	●			
Kwong (2021)	●			
Malahias (2017)	●			
Malahias (2019)	●			
Monto (2014)	●			
Nejati (2017)	●			
Rha (2013)	●	●		
Rodas (2021)	●			
Sari (2020)	●			



M-A:meta-analysis; RCT: randomized controlled trials; SR: systematic review.

Table A2. Comparison of RCTs Included in SRs & M-As for Treatment of Knee or Hip Osteoarthritis


Study	Trams et al (2020) <sup>19</sup>	Johal et al (2019) <sup>10</sup>	Xu et al (2017) <sup>27</sup>	Laudy et al (2015) <sup>20</sup>	Chang et al (2014) <sup>21</sup>
Ahmad (2018)	●				
Bastos (2018)	●				
Bastos (2019)	●				
Buendia-Lopez (2018)	●				
Buendia-Lopez (2019)	●				
Bui (2014)		●			
Cerza (2012)	●		●	●	●
Cole (2017)	●				
Di Martino (2019)	●				
Duif (2015)		●			



M-A:meta-analysis; RCT: randomized controlled trials; SR: systematic review.

Table A3. Comparison of Studies Included in SRs & M-As for Rotator Cuff Repair

Study	Li (2021) <sup>49</sup>	Chen (2020) <sup>48</sup>	Johal (2019) <sup>10, 8<sup>47</sup></sup>	Chen (2018) <sup>47</sup>	Fu (2017) <sup>50</sup>	Zhao (2015) <sup>45</sup>	Moraes (2014) <sup>36</sup>
Antuna (2013)	●		●				●
Carr (2015)		●		●			
Castricini (2011)	●	●	●	●	●	●	●
D'Ambrosi (2016)	●	●					
Ebert (2017)	●	●					
Flury (2016)	●	●	●				



M-A:meta-analysis; SR: systematic review.

## References

1. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci*. Apr 2004; 30(2): 145-51. PMID 15062754
2. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg*. Nov 2004; 114(6): 1502-8. PMID 15509939
3. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol*. Mar 2004; 36(1): 28-35. PMID 15095838
4. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med*. Feb 2011; 39(2): 266-71. PMID 21051428
5. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. *Vox Sang*. Aug 2009; 97(2): 110-8. PMID 19392780
6. Hsu WK, Mishra A, Rodeo SR, et al. Platelet-rich plasma in orthopaedic applications: evidence-based recommendations for treatment. *J Am Acad Orthop Surg*. Dec 2013; 21(12): 739-48. PMID 24292930

7. Masiello F, Pati I, Veropalumbo E, et al. Ultrasound-guided injection of platelet-rich plasma for tendinopathies: a systematic review and meta-analysis. *Blood Transfus.* Mar 2023; 21(2): 119-136. PMID 36346880
8. Dai W, Yan W, Leng X, et al. Efficacy of Platelet-Rich Plasma Versus Placebo in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Trials. *Clin J Sport Med.* Jan 01 2023; 33(1): 69-77. PMID 34342296
9. Muthu S, Patel S, Gobbur A, et al. Platelet-rich plasma therapy ensures pain reduction in the management of lateral epicondylitis - a PRISMA-compliant network meta-analysis of randomized controlled trials. *Expert Opin Biol Ther.* Apr 2022; 22(4): 535-546. PMID 35078375
10. Johal H, Khan M, Yung SP, et al. Impact of Platelet-Rich Plasma Use on Pain in Orthopaedic Surgery: A Systematic Review and Meta-analysis. *Sports Health.* 2019; 11(4): 355-366. PMID 31136726
11. Kearney RS, Ji C, Warwick J, et al. Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial. *JAMA.* Jul 13 2021; 326(2): 137-144. PMID 34255009
12. Seth I, Bulloch G, Seth N, et al. The role of corticosteroid injections in treating plantar fasciitis: A systematic review and meta-analysis. *Foot (Edinb).* Mar 2023; 54: 101970. PMID 36774828
13. Peerbooms JC, Lodder P, den Oudsten BL, et al. Positive Effect of Platelet-Rich Plasma on Pain in Plantar Fasciitis: A Double-Blind Multicenter Randomized Controlled Trial. *Am J Sports Med.* Nov 2019; 47(13): 3238-3246. PMID 31603721
14. Shetty SH, Dhond A, Arora M, et al. Platelet-Rich Plasma Has Better Long-Term Results Than Corticosteroids or Placebo for Chronic Plantar Fasciitis: Randomized Control Trial. *J Foot Ankle Surg.* Jan 2019; 58(1): 42-46. PMID 30448183
15. Johnson-Lynn S, Cooney A, Ferguson D, et al. A Feasibility Study Comparing Platelet-Rich Plasma Injection With Saline for the Treatment of Plantar Fasciitis Using a Prospective, Randomized Trial Design. *Foot Ankle Spec.* Apr 2019; 12(2): 153-158. PMID 29779399
16. Tabrizi A, Dindarian S, Mohammadi S. The Effect of Corticosteroid Local Injection Versus Platelet-Rich Plasma for the Treatment of Plantar Fasciitis in Obese Patients: A Single-Blind, Randomized Clinical Trial. *J Foot Ankle Surg.* 2020; 59(1): 64-68. PMID 31882151
17. Mei-Dan O, Carmont MR, Laver L, et al. Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. *Am J Sports Med.* Mar 2012; 40(3): 534-41. PMID 22253252
18. Anil U, Markus DH, Hurley ET, et al. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. *Knee.* Oct 2021; 32: 173-182. PMID 34500430
19. Trams E, Kulinski K, Kozar-Kaminska K, et al. The Clinical Use of Platelet-Rich Plasma in Knee Disorders and Surgery-A Systematic Review and Meta-Analysis. *Life (Basel).* Jun 25 2020; 10(6). PMID 32630404
20. Laudy AB, Bakker EW, Rekers M, et al. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. *Br J Sports Med.* May 2015; 49(10): 657-72. PMID 25416198
21. Chang KV, Hung CY, Aliwarga F, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. *Arch Phys Med Rehabil.* Mar 2014; 95(3): 562-75. PMID 24291594
22. Meheux CJ, McCulloch PC, Lintner DM, et al. Efficacy of Intra-articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Systematic Review. *Arthroscopy.* Mar 2016; 32(3): 495-505. PMID 26432430
23. Lai LP, Stitik TP, Foye PM, et al. Use of Platelet-Rich Plasma in Intra-Articular Knee Injections for Osteoarthritis: A Systematic Review. *PM R.* Jun 2015; 7(6): 637-48. PMID 25687110
24. Cole BJ, Karas V, Hussey K, et al. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. *Am J Sports Med.* Feb 2017; 45(2): 339-346. PMID 28146403

25. Duymus TM, Mutlu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. *Knee Surg Sports Traumatol Arthrosc.* Feb 2017; 25(2): 485-492. PMID 27056686
26. Kanchanatawan W, Arirachakaran A, Chaijenkij K, et al. Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee. *Knee Surg Sports Traumatol Arthrosc.* May 2016; 24(5): 1665-77. PMID 26387122
27. Xu Z, Luo J, Huang X, et al. Efficacy of Platelet-Rich Plasma in Pain and Self-Report Function in Knee Osteoarthritis: A Best-Evidence Synthesis. *Am J Phys Med Rehabil.* Nov 2017; 96(11): 793-800. PMID 28398969
28. Belk JW, Houck DA, Littlefield CP, et al. Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials. *Arthroscopy.* Jun 2022; 38(6): 2035-2046. PMID 34785294
29. Gazendam A, Ekhtiari S, Bozzo A, et al. Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials. *Br J Sports Med.* Mar 2021; 55(5): 256-261. PMID 32829298
30. Sdeek M, Sabry D, El-Sdeek H, et al. Intra-articular injection of Platelet rich plasma versus Hyaluronic acid for moderate knee osteoarthritis. A prospective, double-blind randomized controlled trial on 189 patients with follow-up for three years. *Acta Orthop Belg.* Dec 2021; 87(4): 729-734. PMID 35172440
31. Reyes-Sosa R, Lugo-Radillo A, Cruz-Santiago L, et al. Clinical comparison of platelet-rich plasma injection and daily celecoxib administration in the treatment of early knee osteoarthritis: A randomized clinical trial. *J Appl Biomed.* Aug 2020; 18(2-3): 41-45. PMID 34907724
32. Elksniņš-Finogejevs A, Vidal L, Peredistijus A. Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up. *J Orthop Surg Res.* Jul 10 2020; 15(1): 257. PMID 32650801
33. Dallari D, Stagni C, Rani N, et al. Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. *Am J Sports Med.* Mar 2016; 44(3): 664-71. PMID 26797697
34. Nouri F, Babaee M, Peydayesh P, et al. Comparison between the effects of ultrasound guided intra-articular injections of platelet-rich plasma (PRP), high molecular weight hyaluronic acid, and their combination in hip osteoarthritis: a randomized clinical trial. *BMC Musculoskelet Disord.* Sep 12 2022; 23(1): 856. PMID 36096771
35. Dallari D, Savarino L, Stagni C, et al. Enhanced tibial osteotomy healing with use of bone grafts supplemented with platelet gel or platelet gel and bone marrow stromal cells. *J Bone Joint Surg Am.* Nov 2007; 89(11): 2413-20. PMID 17974883
36. Moraes VY, Lenza M, Tamaoki MJ, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. *Cochrane Database Syst Rev.* Apr 29 2014; 2014(4): CD010071. PMID 24782334
37. Lv ZT, Zhang JM, Pang ZY, et al. The efficacy of platelet rich plasma on anterior cruciate ligament reconstruction: a systematic review and meta-analysis. *Platelets.* Feb 17 2022; 33(2): 229-241. PMID 34048294
38. Nin JR, Gasque GM, Azcárate AV, et al. Has platelet-rich plasma any role in anterior cruciate ligament allograft healing?. *Arthroscopy.* Nov 2009; 25(11): 1206-13. PMID 19896041
39. Ye Z, Chen H, Qiao Y, et al. Intra-Articular Platelet-Rich Plasma Injection After Anterior Cruciate Ligament Reconstruction: A Randomized Clinical Trial. *JAMA Netw Open.* May 01 2024; 7(5): e2410134. PMID 38728032
40. Bailey L, Weldon M, Kleihege J, et al. Platelet-Rich Plasma Augmentation of Meniscal Repair in the Setting of Anterior Cruciate Ligament Reconstruction. *Am J Sports Med.* Oct 2021; 49(12): 3287-3292. PMID 34477016

41. Griffin XL, Achten J, Parsons N, et al. Platelet-rich therapy in the treatment of patients with hip fractures: a single centre, parallel group, participant-blinded, randomised controlled trial. *BMJ Open*. Jun 25 2013; 3(6). PMID 23801709
42. Griffin XL, Wallace D, Parsons N, et al. Platelet rich therapies for long bone healing in adults. *Cochrane Database Syst Rev*. Jul 11 2012; (7): CD009496. PMID 22786528
43. Calori GM, Tagliabue L, Gala L, et al. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. *Injury*. Dec 2008; 39(12): 1391-402. PMID 19027898
44. Samuel G, Menon J, Thimmaiah S, et al. Role of isolated percutaneous autologous platelet concentrate in delayed union of long bones. *Eur J Orthop Surg Traumatol*. Jul 2018; 28(5): 985-990. PMID 29167980
45. Zhao JG, Zhao L, Jiang YX, et al. Platelet-rich plasma in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. *Arthroscopy*. Jan 2015; 31(1): 125-35. PMID 25278352
46. Yang J, Sun Y, Xu P, et al. Can patients get better clinical outcomes by using PRP in rotator cuff repair: a meta-analysis of randomized controlled trials. *J Sports Med Phys Fitness*. Nov 2016; 56(11): 1359-1367. PMID 26473444
47. Chen X, Jones IA, Park C, et al. The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment. *Am J Sports Med*. Jul 2018; 46(8): 2020-2032. PMID 29268037
48. Chen X, Jones IA, Togashi R, et al. Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: A Systematic Review and Meta-analysis With Bias Assessment. *Am J Sports Med*. Jul 2020; 48(8): 2028-2041. PMID 31743037
49. Li Y, Li T, Li J, et al. Platelet-Rich Plasma Has Better Results for Retear Rate, Pain, and Outcome Than Platelet-Rich Fibrin After Rotator Cuff Repair: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Arthroscopy*. Feb 2022; 38(2): 539-550. PMID 34052384
50. Fu CJ, Sun JB, Bi ZG, et al. Evaluation of platelet-rich plasma and fibrin matrix to assist in healing and repair of rotator cuff injuries: a systematic review and meta-analysis. *Clin Rehabil*. Feb 2017; 31(2): 158-172. PMID 26928856
51. Randelli PS, Stoppani CA, Santarsiero G, et al. Platelet-Rich Plasma in Arthroscopic Rotator Cuff Repair: Clinical and Radiological Results of a Prospective Randomized Controlled Trial Study at 10-Year Follow-Up. *Arthroscopy*. Jan 2022; 38(1): 51-61. PMID 34052372
52. Rossi LA, Gorodischer TD, Camino P, et al. Leukocyte-Poor Platelet-Rich Plasma as an Adjuvant to Arthroscopic Rotator Cuff Repair Reduces the Retear Rate But Does Not Improve Functional Outcomes: A Double-Blind Randomized Controlled Trial. *Am J Sports Med*. May 2024; 52(6): 1403-1410. PMID 38587033
53. Yao L, Pang L, Zhang C, et al. Platelet-Rich Plasma for Arthroscopic Rotator Cuff Repair: A 3-Arm Randomized Controlled Trial. *Am J Sports Med*. Dec 2024; 52(14): 3495-3504. PMID 39425250
54. Kubota G, Kamoda H, Orita S, et al. Platelet-rich plasma enhances bone union in posterolateral lumbar fusion: A prospective randomized controlled trial. *Spine J*. Feb 2019; 19(2): e34-e40. PMID 28735763
55. Carreon LY, Glassman SD, Anekstein Y, et al. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. *Spine (Phila Pa 1976)*. May 01 2005; 30(9): E243-6; discussion E247. PMID 15864142
56. Tsai CH, Hsu HC, Chen YJ, et al. Using the growth factors-enriched platelet glue in spinal fusion and its efficiency. *J Spinal Disord Tech*. Jun 2009; 22(4): 246-50. PMID 19494743
57. Everts PA, Devilee RJ, Brown Mahoney C, et al. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome. A prospective randomized double-blind study. *Eur Surg Res*. 2008; 40(2): 203-10. PMID 17998780

58. Shu H, Huang Z, Bai X, et al. The Application of Platelet-Rich Plasma for Patients Following Total Joint Replacement: A Meta-Analysis of Randomized Controlled Trials and Systematic Review. *Front Surg.* 2022; 9: 922637. PMID 35860197
59. American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee (Non-Arthroplasty). 2021; <https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/oak3cpg.pdf>. Accessed March 2, 2025.
60. American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline. 2023; <https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-hip/oah-cpg.pdf>. Accessed March 3, 2025.
61. American Academy of Orthopaedic Surgeons. Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline. <https://www.orthoguidelines.org/topic?id=1027>. Published March 11, 2019. Accessed March 1, 2025.
62. National Institute for Health and Care Excellence (NICE). Autologous blood injection for tendinopathy [IPG438]. 2013; <https://www.nice.org.uk/guidance/ipg438>. Accessed March 2, 2025.
63. National Institute for Health and Care Excellence (NICE). Autologous blood injection for plantar fasciitis [IPG437]. 2013; <https://www.nice.org.uk/guidance/ipg437>. Accessed March 3, 2025.
64. National Institute for Health and Care Excellence (NICE). Platelet-rich plasma injections for knee osteoarthritis [IPG637]. 2019; <https://www.nice.org.uk/guidance/ipg637>. Accessed March 1, 2025.

## Documentation for Clinical Review

### Please provide the following documentation:

- History and physical and/or consultation notes including:
  - Clinical findings (i.e., pertinent symptoms and duration)
  - Comorbidities
  - Activity and functional limitations
  - Family history, if applicable
  - Reason for procedure/test/device, when applicable
  - Pertinent past procedural and surgical history
  - Past and present diagnostic testing and results
  - Prior conservative treatments, duration, and response
  - Treatment plan (i.e., surgical intervention)
- Consultation and medical clearance report(s), when applicable
- Radiology report(s) and interpretation (i.e., MRI, CT, discogram)
- Laboratory results
- Other pertinent multidisciplinary notes/reports: (i.e., psychological or psychiatric evaluation, physical therapy, multidisciplinary pain management), when applicable

### Post Service (in addition to the above, please include the following):

- Results/reports of tests performed
- Procedure report(s)

## Coding

*The list of codes in this Medical Policy is intended as a general reference and may not cover all codes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy.*

Type	Code	Description
CPT®	0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
HCPCS	C1734	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)
	P9020	Platelet rich plasma, each unit

## Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
12/01/2025	New policy.

## Definitions of Decision Determinations

**Healthcare Services:** For the purpose of this Medical Policy, Healthcare Services means procedures, treatments, supplies, devices, and equipment.

**Medically Necessary or Medical Necessity** means reasonable and necessary services to protect life, to prevent significant illness or significant disability, or alleviate severe pain through the diagnosis or treatment of disease, illness, or injury, as required under W&I section 14059.5(a) and 22 CCR section 51303(a). Medically Necessary services must include services necessary to achieve age-appropriate growth and development, and attain, maintain, or regain functional capacity.

For Members less than 21 years of age, a service is Medically Necessary if it meets the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) standard of Medical Necessity set forth in 42 USC section 1396d(r)(5), as required by W&I sections 14059.5(b) and 14132(v). Without limitation, Medically Necessary services for Members less than 21 years of age include all services necessary to achieve or maintain age-appropriate growth and development, attain, regain or maintain functional capacity, or improve, support, or maintain the Member's current health condition. Contractor must determine Medical Necessity on a case-by-case basis, taking into account the individual needs of the Child.

## Criteria Determining Experimental/Investigational Status

In making a determination that any procedure, treatment, therapy, drug, biological product, facility, equipment, device, or supply is "experimental or investigational" by the Plan, the Plan shall refer to evidence from the national medical community, which may include one or more of the following sources:

1. Evidence from national medical organizations, such as the National Centers of Health Service Research.
2. Peer-reviewed medical and scientific literature.
3. Publications from organizations, such as the American Medical Association (AMA).
4. Professionals, specialists, and experts.
5. Written protocols and consent forms used by the proposed treating facility or other facility administering substantially the same drug, device, or medical treatment.
6. An expert physician panel selected by one of two organizations, the Managed Care Ombudsman Program of the Medical Care Management Corporation or the Department of Managed Health Care.

## Feedback

Blue Shield of California Promise Health Plan is interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration. Our medical policies are available to view or download at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

For medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

Questions regarding the applicability of this policy should be directed to the Blue Shield of California Promise Health Plan Prior Authorization Department at (800) 468-9935, or the Complex Case Management Department at (855) 699-5557 (TTY 711) for San Diego County and (800) 605-2556 (TTY 711) for Los Angeles County or visit the provider portal at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

*Disclaimer: Blue Shield of California Promise Health Plan may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as member health services contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member health services contracts may differ in their benefits. Blue Shield of California Promise Health Plan reserves the right to review and update policies as appropriate.*